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Abstract
Non-inflammatory odontogenic cysts and tumours vary in clinical appearance and can
cause widespread destruction and deformation of the face. Proteases may play a role in the
differing pathogenesis of these cysts and tumours. Human kallikrein proteins (KLKs) are a
group of 15 serine proteases implicated in a variety of signalling and regulatory roles. This
study evaluated the ameloblastoma, keratocystic odontogenic tumour (KOT), dentigerous
cyst, lateral periodontal cyst, nasopalatine duct cyst and odontoma for the presence of KLK
3, 4, 5, 9 and 11 utilizing immunohistochemistry. Secondarily, we evaluated ameloblastoma
for expression of KLK 1-15 mRNA using reverse transcription-polymerase chain reaction.
Immunostaining identified KLK 3, 4, 9 & 11 in all tissue types and KLK 5 only in KOT’s.
The ameloblastoma expressed KLK 1, 4, 7, 8, 10 & 12 mRNA. For the first time KLK 3, 4,
5, 9 & 11 were identified in maxillofacial cysts and tumours.

Keywords
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Chapter 1

1

Embryology of the Oral and Maxillofacial Complex
Knowledge of the formation of the tissues comprising the face, mouth and jaws is

essential in order to understand the pathogenesis of developmental oral and maxillofacial
lesions. Despite the complexity and large breadth of this topic, a concise review will be
presented in this chapter in order to provide a foundation for the subsequent discussion of
various odontogenic and non-odontogenic pathologies.

1.1

The Developing Maxillofacial Complex
The first three weeks of embryonic development yield a three layered embryo

composed of ectoderm, mesoderm and endoderm. Over the next seven weeks,
developmental changes will occur forming the basis for the major structural components
of the head and neck.
Folding of the trilaminar embryo at approximately three weeks results in
formation of the stomodeum, an ectodermal lined primitive oral cavity separated from the
gut by the buccopharyngeal membrane. The buccopharyngeal membrane is a bilayered
structure composed of ectoderm and endoderm which will eventually break down,
facilitating a connection between the oral cavity and gut. Lateral to the stomodeum are
the branchial arches, structures of neural crest origin. Neural crest cells arise from the
lateral aspect of the neural plate, as it folds to form the neural tube. These neural crest
cells undergo an epithelial to mesenchymal transition, and subsequent migration away
from the neural tube (1). Tissues derived from the neural crest (including cranial bone,
alveolar bone, dentin and periodontal ligament) are considered ectomesenchymal in
origin, reflecting the neuroectodermal embryologic basis (2). Development of the neural
crest is a crucial step in formation of a normal anatomic maxillofacial complex.
Abnormalities ranging from alterations in dental development, to craniofacial syndromes
such as Treacher-Collins syndrome may result due to improper development of the neural
crest.
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Five paired branchial arches (numbered I-IV and VI) are oriented in a rostralcaudal relationship form along the lateral walls of the developing pharynx. Branchial
grooves separate the arches laterally, while pharyngeal grooves separate the arches
medially. Growth of these arches separates the stomodeum from the cardiac bulge (2).
Branchial arches are composed of an outer ectodermal surface, inner endodermal surface,
and central core composed of mesoderm and ectomesenchyme which gives rise to
cartilage in each arch. The first branchial arch forms rostrally to the buccopharyngeal
membrane; as a result it has an ectodermal inner aspect as opposed to the endodermal
inner aspect as found in the remaining four arches. Each arch has a vascular and nerve
supply consisting of sensory and motor branches(2). Anatomic muscular, skeletal and
nervous derivatives from each branchial arch are noted in Table 1 (3).
Table 1.1: Branchial Arch Derivatives
Arch Number

Muscle(s)

Nerve

Skeletal

Anterior belly of
digastric,
mylohyoid, tensor
tympani, tensor
palatini, temporalis,
masseter, medial
pterygoid, lateral
pterygoid
Muscles of facial
expression,
stapedius,
stylohyoid, posterior
belly of digastric

Trigeminal (CN V)

Meckel’s Cartilage:
mandible, maxilla
incus, malleus,
sphenomandibular
ligament,
sphenomalleolar
ligament

Facial (CN VII)

III

Stylopharyngeus

Glossopharyngeal
(CN IX)

IV

Pharyngeal
Vagus (X)
constrictors,
laryngeal
musculature
Sternocleidomastoid, Spinal Accessory
trapezius
(XI)

Reichert’s Cartilage:
Hyoid bone (lesser
cornu, upper part of
body), stapes,
styloid process of
temporal bone,
stylohyoid ligament,
Hyoid bone (greater
cornu, lower part of
body)
Laryngeal cartilage

I

II

VI
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Initially, the stomodeum is bounded rostrally by the first branchial arch’s frontal
prominence, and caudally by the cardiac bulge. Maturation and development of the
branchial arches results in the first, second and third branchial arches forming the floor of
the stomodeum as the cardiac bulge is displaced caudally. Between three to four weeks,
the first branchial arch forms bilateral (lateral) maxillary processes and (inferior/caudal)
mandibular processes which enclose the stomodeum. The frontal prominence gives rise
to the medial nasal process, lateral nasal process and nasal pits in the fourth to fifth
weeks. Development of the external face during week five to six results in medial
ingrowth of the maxillary processes, resulting in fusion of the right and left medial nasal
processes at the midline, and ultimately the maxillary processes with the central medial
nasal processes. As the maxillary/midface development occurs, the mandibular processes
fuse in the midline forming the lower lip. Fusion of the aforementioned facial processes
during weeks four to six establishes the support and structure required for normal
odontogenesis. Areas of odontogenic epithelium arise from thickening of the epithelium
along the inferior border of the maxillary process as well as the superior border of the
mandibular process as early as week four. Once these facial processes fuse (typically by
day thirty-seven), a continuous odontogenic epithelial thickening known as the primary
epithelial band is formed in the primitive maxilla and mandible (2).

1.2

Odontogenesis
Odontogenesis, the formation of teeth, is a complex process involving maturation,

morphogenesis and histodifferentiation of the maxillary and mandibular primary
epithelial bands. The dental lamina and vestibular lamina arise from the primary
epithelial band. The vestibule arises due to ingrowth of the vestibular lamina into the
underlying ectomesenchyme. Prior to vestibular lamina ingrowth, the dental lamina forms
as placodes, areas of thickening of the epithelial band form along the primary band.
These epithelial placodes will grow/bud into the underlying mesenchyme, signaling the
mesenchyme to condense around them (4). Normal tooth development occurs in three
classic stages following the aforementioned events of initiation. The bud, cap and bell
stages constitute morphogenesis in tooth development (4). Differentiation begins to occur
in the late bell stage, and continues throughout development yielding mature teeth.
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1.2.1

Bud Stage
The bud stage is characterized by the invagination of the primary epithelial band

into the ectomesenchyme. As mentioned, the dental lamina is the epithelial connection
between the oral epithelium and the newly formed tooth bud. Ectomesenchymal tissue in
the vicinity of the epithelial bud condenses in response to the bud ingrowth. The
transition from bud to cap stage is the initiation of the morphologic difference between
tooth buds, ultimately leading to different shapes of teeth (2).

1.2.2

Cap Stage
Odontogenesis continues with further growth of each bud into the underlying

connective tissue, ‘dragging’ the dental lamina with it. Once an appropriate depth is
reached, the basal cells at the tip of the bud proliferate and extend inferiorly and laterally
forming a concavity, the early cap stage of odontogenesis (5). Continued development of
the cap stage results in a separation of the top and bottom layers of odontogenic
epithelium, forming the outer enamel epithelium (superficial layer) and inner enamel
epithelium (deep layer). This developing structure is referred to as the enamel organ (2).
As the distance between the inner and outer enamel epithelium increases, the space is
occupied by an increasing number of star shaped epithelial cells known as the stellate
reticulum. Glycosaminoglycans secreted into this central space (between epithelial
layers) lead to water inflow and increasing space between the epithelial cells (2).
The cap stage is named as a result of the shape of the enamel organ which overlies
the condensed ectomesenchyme/dental papilla. Ectomesenchyme surrounding the
periphery of the cap/enamel organ/epithelium is termed the dental follicle. The dental
follicle will form marginal gingiva as well as the periodontal ligament, connecting
cementum of the tooth to alveolar bone (5). Further elongation at the periphery of the
cap, and histodifferentiation of cells of epithelial and ectomesenchymal origin leads to
the next stage of development, the bell stage.
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1.2.3

Bell Stage
The bell stage is characterized by continued growth, morphodifferentiation

(forming the shape of the crown of the tooth) and histodifferentiation of the inner enamel
epithelium cells into elongated, columnar, palisaded cells with nuclei located opposite the
underlying connective tissue/basement membrane. This reverse polarization identifies
the differentiation of these cells into immature ameloblasts (enamel forming cells). Bell
stage inner enamel epithelium induces the surrounding ectomesenchymal connective
tissue to change form, ultimately resulting in the mature dental papilla, tissue that will
become the future pulp of the tooth. In response to the reverse polarization of the
immature ameloblasts, ectomesenchymal cells adjacent to the ameloblasts differentiate
into a layer of palisaded immature odontoblasts which oppose the ameloblast basement
membrane.
Inner enamel epithelium/ameloblasts and the outer enamel epithelium maintain
continuity at the deepest aspect of the developing bell. The cervical loop is the point at
which the concavity of the bell has a point of inflexion and transition from inner enamel
epithelium/ameloblast to outer enamel epithelium occurs. A new layer of cells forms via
differentiation from the stellate reticulum. This layer, the stratum intermedium assists in
production of enamel and lies between the stellate reticulum and inner enamel
epithelium. Late bell stage is characterized by secretion of the dentin matrix by
odontoblasts, which subsequently stimulates secretion of enamel matrix by the
ameloblasts (5).

1.2.4

Late Odontogenesis
Above the developing tooth, dental lamina forms small, discontinuous islands of

residual epithelium in the connective tissue. These are termed the cell rests of Serres.
Ameloblasts/outer enamel epithelium remaining after tooth formation constitutes the
reduced enamel epithelium, a layer of epithelial cells surrounding the crown of the tooth.
Odontoblasts at the deep aspect of the bell, away from the oral cavity are responsible for
dentin matrix production for formation of the tooth root. Dentin production induces
adjacent dental follicle tissue to differentiate into cementoblasts, the cells responsible for
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production of cementum, the outer component of the root. Upon completion of dentin
formation, these odontoblasts (forming the Hertwig’s root sheath) fragment into islands
of epithelial cells known as the cells rests of Malassez. Cell rests of Malassez remain in
the periodontal ligament (if present) throughout life (5).
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Chapter 2

2

Oral and Maxillofacial Pathology
Oral and maxillofacial pathology is the broad area of study and investigation of

developmental, genetic, acquired or functional abnormalities of the oral and maxillofacial
region. Medical and dental professionals including specialists and generalists deal with
pathology in the mouth, face, jaws and neck on a regular basis. Odontogenic tissues lead
to a small but unique subset of head and neck disease as they may involve multiple
embryologic tissues in one pathologic process. These diseases/disorders may be benign
or malignant, with significant variation in prognosis and treatment.

2.1

Non-Inflammatory Odontogenic Cysts
Epithelial lined cysts within bone are rare apart from the oral and maxillofacial

region (6). Odontogenic cysts can be classified as neoplastic, developmental or
inflammatory. Inflammatory odontogenic cysts including the radicular cyst and buccal
bifurcation cyst form as a result of inflammation, often caused by pulpal disease of the
tooth. Developmental odontogenic cysts are of unknown cause, and can form anywhere
that odontogenic tissue is/has been present. Examples of developmental odontogenic
cysts are the dentigerous cyst, lateral periodontal cyst, eruption cyst, gingival cyst of the
adult, glandular odontogenic cyst and the orthokeratinizing odontogenic cyst. Cystic
neoplasms include the keratocystic odontogenic tumour and the calcifying cystic
odontogenic tumor.
The clinical presentation, radiographic appearance and histologic features of these
lesions are quite variable. Non-inflammatory odontogenic cysts may present as
radiographic change visible on routine dental imaging. Rarely, they may present as a
result of a pathologic fracture of bone through the cystic structure. Odontogenic cysts
should be considered in the differential diagnosis for expansile lesions of the jaws, as
well as non-expansile radiolucencies on routine radiographic examination. A discussion
of the clinical behavior, histology and treatment of odontogenic cysts studied as part of
this project is included in the following text.
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2.1.1

Dentigerous Cyst
The dentigerous cyst is the most common non-inflammatory odontogenic cyst,

representing 20% of all of these lesions (6). Dentigerous cysts occur in association with
an unerupted tooth, most commonly associated with mandibular third molars. A smaller
proportion are associated with maxillary third molars, maxillary canines and mandibular
premolars (7). Deciduous teeth are very rarely associated with dentigerous cysts. There
is a male predilection, with common age of presentation ranging from the teens to fifth
decade of life (6, 8). Fluid accumulation between the reduced enamel epithelium and
enamel of the affected teeth is believed to account for the formation of these cysts (7).
Dentigerous cysts present in a variety of scenarios ranging from small, painless cysts with
minimal bony destruction to large cysts with bony expansion. They may become infected
when occurring with a partially erupted tooth, or as a result of association with a
periodontal or pericoronal lesion of an adjacent tooth resulting in inflammatory change
around the cyst, pain and potentially suppuration (6).
Radiographically, these cysts typically present as a unilocular radiolucency with a
well-defined sclerotic border arising from the cemento-enamel junction (CEJ) of the
affected impacted tooth. The crown of the impacted affected tooth is surrounded by the
cyst in the central dentigerous cyst (described above). The lateral dentigerous cyst
presents with the cyst developing laterally along the root surface enclosing one side of the
root and the crown of the tooth. The very rare circumferential variety of dentigerous cyst
is present when it appears that the entire root and crown of the tooth are enveloped by the
cyst (7). It is possible to have displacement of the associated tooth as a result of the
dentigerous cyst’s growth. If displacement occurs, the mandibular third molar may be
displaced to the inferior border of the mandible, or superiorly into the ramus of the
mandible (6). Radiographic studies are inadequate to confirm a diagnosis of dentigerous
cyst. Small cysts and hyperplastic dental follicles may present with similar radiographic
features. As a result, pericoronal tissue removed with impacted wisdom teeth should be
submitted for histopathologic analysis if a pre-operative radiolucency of greater than
about 5 mm is detected (7) (9).
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Histologically the dentigerous cyst is composed of a non-keratinized stratified
squamous epithelial. The presence of nodular epithelial thickenings has been noted and
must be examined to rule out neoplastic change (6). There is often a thin fibrous
connective tissue wall composed of immature fibroblasts separated by ground substance
and a stroma rich in mucopolysaccharides (10). If inflamed, the connective tissue wall
will exhibit more collagen and an infiltration of inflammatory cells.
Although reports exist describing the transition of dentigerous cyst to squamous
cell carcinoma, ameloblastoma or intraosseous mucoepidermoid carcinoma, the
occurrence is rare (6). Treatment of dentigerous cysts usually involves surgical
enucleation with extraction of the associated tooth. Large dentigerous cysts may be
treated with marsupialization and subsequent enucleation of a smaller cyst, resulting in a
smaller bony defect (7, 11). Recurrence after enucleation is rare.

2.1.2

Lateral Periodontal Cyst
The lateral periodontal cyst is a developmental odontogenic cyst that usually

occurs lateral to the root surface of a tooth, most commonly arising in the mandibular
premolar region while in the maxilla, they often occur between the canine and lateral
incisor teeth (6). Gingival cysts of the adult are histopathologically similar to the lateral
periodontal cyst but instead of presenting as an intrabony cyst, are found in the gingiva.
Lateral periodontal cysts are relatively rare, constituting less than 2% of epithelial lined
maxillofacial cysts (6). Remnants of the dental lamina within bone are believed to give
rise to the lateral periodontal cyst (11). Lateral periodontal cysts most commonly present
between the fifth and seventh decades of life with a 2:1 male:female predilection (11).
Lateral periodontal cysts are often asymptomatic and detected as a result of
routine dental radiography. Radiographically, these cysts are usually well defined, round
or tear-dropped shaped radiolucencies presenting lateral to the roots of premolar or
canine teeth. Lateral periodontal cysts are not commonly associated with tooth root
divergence or root destruction (11). Lesions greater than 1 cm in diameter are rare.
Occasionally a polycystic radiographic appearance may be present consistent with the
histopathologic diagnosis of a botryoid odontogenic cyst (6).
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Diagnosis of a lateral periodontal cyst is based on histopathologic examination.
Inflammatory cysts such as a radicular cyst from an accessory root canal may appear with
similar radiographic presentation to the lateral periodontal cyst. Histopathologic
characteristics of the lateral periodontal cyst include a fibrous wall with thin squamous or
cuboidal non-keratinized epithelial lining (one – three cells thick in most areas) with or
without the presence of nodular focal thickenings composed primarily of clear cells (6).
Botryoid odontogenic cysts may present with multiple lateral periodontal cysts and focal
areas similar to that seen in glandular odontogenic cysts (6).
Surgical curettage and enucleation are the treatment of choice for lateral
periodontal cysts. Recurrence is rare, however a higher risk of recurrence is noted for the
botryoid odontogenic cyst (11).

2.2

Benign Odontogenic Tumours
Benign odontogenic tumours may originate from epithelial tissue,

ectomesenchymal connective tissue or a combination of both (mixed tumours). These
tumours originate in the mandible or maxilla, and form from tissue required for normal
odontogenesis. Examples of epithelial odontogenic tumours are the ameloblastoma,
keratocystic odontogenic tumour, calcifying epithelial odontogenic tumour and
adenomatoid odontogenic tumour. Connective tissue/mesenchymal tumours include the
odontogenic fibroma, odontogenic myxoma and the cementoblastoma. Mixed (both
epithelial and mesenchymal/connective tissue origin) odontogenic tumours include the
ameloblastic fibroma, and ameloblastic fibro-odontoma.
A review of the ameloblastoma and keratocystic odontogenic tumour will be
presented in this chapter.

2.2.1

Ameloblastoma
The ameloblastoma is a benign odontogenic neoplasm originating from

odontogenic epithelial cells in the jaws/mouth. Ameloblastomas are slow growing,
locally aggressive tumours with limitless growth potential and a high rate of recurrence.
If left untreated they may cause significant destruction of facial form, including
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compression of vital structures such as nearby vasculature and nerves. These tumours are
the second most common clinically significant benign epithelial odontogenic tumour
(following the keratocystic odontogenic tumour) (6, 7). Sources of the neoplastic
epithelial cells in ameloblastomas include the oral epithelium, cell rests of Serres, cell
rests of Malassez, lining of odontogenic cysts and the reduced enamel epithelium (11).
The pathogenesis of the ameloblastoma is partially attributable to a number of known
altered protein levels. Overexpression of the anti-apoptotic proteins B cell lymphoma-2
protein (BCL-2) and B cell lymphoma–XL protein (BCL-XL), tumour necrosis factor
alpha (TNF-α), fibroblast growth factor (FGF), interleukin 1 (IL-1), interleukin 6 (IL-6)
and matrix metaloproteinases (MMP) are identified in ameloblastoma tissue. Expression
of altered laminin 5 has been identified at the epithelial interface (7, 11).
Ameloblastomas also show a low cell proliferation rate based on staining for the protein
Ki-67 (11). Despite this knowledge about altered levels of protein such as growth
factors, cell signaling molecules and cytokines, knowledge regarding a stimulus for
neoplastic transformation of the odontogenic epithelial cells remains unknown (11).
Although metastasis has been reported, it is extremely rare, reinforcing its classification
as a benign neoplasm.
Ameloblastomas are classified based on their histologic characteristics and
general clinical form. Three major classifications clinically are identified: the
conventional solid/common/multicystic/polycystic ameloblastoma, the unicystic
ameloblastoma and peripheral (extraosseous) ameloblastoma.
The solid/common/multicystic/polycystic ameloblastoma is the most prevalent
type of ameloblastoma comprising approximately 86% of all ameloblastomas (6). It
presents most often in the posterior mandible of patients aged 20 – 70. No gender or
racial predilection is noted. These slowly growing tumours may present
asymptomatically on routine dental radiography or with painless bony expansion and/or
displacement of teeth in the affected area of bone. Radiographically these tumours
appear as well defined radiolucencies, often multilocular in nature. Buccal and lingual
cortical expansion or perforation are often seen, and destruction of tooth roots in the
vicinity of the lesion is common (7). Differential diagnosis based on clinical and
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radiographic examination includes other odontogenic and non-odontogenic cysts and
tumours. As a result, histopathology is required for diagnosis. Six histologic subtypes of
the solid/multicystic ameloblastoma are recognized. These include the follicular,
plexiform, acanthomatous, granular cell, desmoplastic and the basal cell types (6, 7).
Follicular and plexiform subtypes are the most common while the basal cell variant is the
least common (7). The follicular pattern exhibits reverse polarized peripheral columnar
epithelial cells, surrounding a stellate reticulum like core. Plexiform variant tumours
have anastomosing cords of odontogenic epithelium with reverse polarized ameloblastlike cells lining the periphery of these cords. The solid ameloblastoma tends to infiltrate
between intact cancellous bony trabeculae beyond the radiographic border of the tumour
(12). Radiographically evident bony destruction is not seen at the margin of tumour
invasion. Treatment by simple enucleation and curettage results in recurrence rates
ranging from 50-90% (6). As a result, osseous resection 1.0-1.5 cm beyond the
radiographic margin is recommended. Soft tissue should be resected such that one
uninvolved tissue plane is included in the resection margin (7).
The unicystic ameloblastoma represents roughly 13% of ameloblastomas. It is
more commonly seen in younger patients with an average age of presentation of 22.1
years (7). Fifty percent of unicystic ameloblastomas present during teenage years (6).
Unicystic ameloblastomas present in the mandible in 90% of cases, often as a painless
swelling which surrounds the crown of an unerupted tooth. Radiographic presentation is
usually a well-defined, corticated radiolucency which may be confused with the
presentation of a dentigerous cyst, keratocystic odontogenic tumour, residual or radicular
cyst (depending on location) (6). Three histologic variants are identified. These include
the luminal, intraluminal and mural unicystic ameloblastomas. Luminal unicystic
ameloblastomas have tumour cells located only in the luminal aspect of the cyst. They
are surrounded by a fibrous wall and the cystic lining is composed of reverse polarized,
palisaded columnar or cuboidal hyperchromatic basal cells (6). Intraluminal unicystic
ameloblastomas exhibit intraluminal masses/nodules of ameloblastic cells often with the
plexiform pattern seen in solid ameloblastomas. Inflammation may also be seen in the
intraluminal aspect of the cyst. In the mural unicystic ameloblastoma, invasion of islands
of epithelial cells resembling plexiform or follicular solid ameloblastomas are seen in the
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fibrous wall of the cyst (6). Treatment of the unicystic ameloblastoma is dependent on a
number of factors including tumour size, location and histologic subclassification.
Intraluminal and luminal unicystic ameloblastomas can be successfully treated with
enucleation and curettage. The rate of recurrence after enucleation and curettage of these
tumours is 10-30% (7, 13). Mural unicystic ameloblastomas should be treated similarly
to the solid ameloblastoma, with a 1.0-1.5 cm bony resection margin as well as inclusion
of one uninvolved tissue plane for soft tissue management (7). Block resection as
described for the mural unicystic ameloblastoma is also indicated for recurrent
intraluminal or luminal unicystic ameloblastomas, as well as for very large unicystic
ameloblastomas that occupy such significant portions of the jaw that enucleation would
leave little to no bony structure remaining (7).
The peripheral ameloblastoma is the least common variant, accounting for about
1% of all ameloblastomas. The average age of presentation is 52, with most tumours
presenting in middle aged adults (6). Clinical presentation is usually a non-ulcerated,
sessile or pedunculated lesion of the gingiva or alveolar mucosa, consistent with the
presentation of an oral epulis. Peripheral ameloblastomas do not invade bone, but may
cause superficial bony erosion (7, 13). Histologically, these tumours may present with
the patterns described for any of the solid ameloblastomas, most commonly resembling
the plexiform or follicular variants (6). It is possible for the tumour to be sub-epithelial,
or in communication with the mucosal/gingival epithelium. Treatment for peripheral
ameloblastomas involves wide local excision. If margins are negative, recurrence is rare
(7). Malignant transformation has been noted, but is quite rare (6).

2.2.2

Keratocystic Odontogenic Tumour
The keratocystic odontogenic tumour (KOT) is a cystic neoplasm of odontogenic

origin. Previously known as the odontogenic keratocyst, it is now classified by the World
Health Organization as a benign odontogenic neoplasm as a result of mutations identified
in the patched 1 (PTCH1) tumour suppressor gene (14, 15). While odontogenic cysts of
the jaws and oral cavity are generally believed to enlarge as a result of osmotic pressure
within the cyst lumen, the KOT enlarges as a result of intrinsic mitotic growth of the
tumour cells. KOTs express bone resorptive cytokines/factors interleukin-1 (IL-1), IL-6,
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and parathyroid hormone related peptide (PHRP) (7). Proliferating cell nuclear antigen
(PCNA) has also been identified in KOTs and Slootweg (16) identified increased
proliferative activity in KOTs compared to other odontogenic cysts. (KOT growth can
also be attributed to mutations in the PTCH1 tumour suppressor gene, which usually
functions as a membrane receptor, forming a complex with the sonic hedgehog protein to
control growth and cell division). When mutated, the PTCH1 gene fails to suppress
tumour growth, resulting in enlargement and expansion of the KOT. The PTCH1 gene
and KOTs are associated with the nevoid basal cell carcinoma syndrome/Gorlin-Goltz
syndrome. Gorlin-Goltz syndrome has a prevalence of 1 in 60,000 (6). It exhibits
autosomal dominant inheritance, however 35-50% of cases are due to de novo mutations
(6). The most prominent findings (present in >50% of patients) in Gorlin-Goltz
syndrome include multiple basal cell carcinomas, multiple KOTs, epidermal cysts,
palmar/plantar pitting, bifid ribs, calcified falx cerebri, ocular telorism, frontal bossing
with enlarged head circumference and spina bifida occulta of cervical or thoracic
vertebrae (6). KOTs in patients with nevoid basal cell carcinoma syndrome/Gorlin-Goltz
syndrome often exhibit satellite cysts and islands of epithelial rests within the cystic
capsule. Compared to non-syndromic KOTs, syndromic KOTs show higher levels of
tumour suppressor p53 and cyclin-D1(6). Syndromic patients with KOTs should be
followed for recurrence. Due to the higher risk of KOTs in these patients, infected KOTs
in patients with Gorlin-Goltz syndrome are relatively common compared to the nonsyndromic population (6).
KOTs occur in patients of all ages, most commonly presenting in those aged 10 –
40 (6). Roughly 5% of all patients presenting with KOTs will have multiple lesions and
an additional 5% will present with Gorlin-Goltz syndrome (11). A small male
predilection is noted, and 60-80% of cases involve the mandible, most commonly the
ascending ramus and posterior body (7). They are hypothesized to form from cells of the
dental lamina, so can form anywhere odontogenesis occurs (6). KOTs may also arise in
the mucosa as a result of daughter cysts located between an old cyst and the mucosa (17).
Radiographic presentation includes unilocular or multilocular radiolucencies with welldefined corticated borders. They may present with an unerupted tooth involved with the
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tumour. A clinical differential diagnosis would commonly include an ameloblastoma,
dentigerous cyst, and odontogenic myxoma.
Histopathologic diagnosis is made based on microscopic findings including a cyst
usually 6-8 cells thick, with a hyperchromatic palisaded basal layer of cuboidal or
columnar epithelial cells. A corrugated but flattened parakeratin layer is noted on the
luminal aspect of the cyst. Occasionally, focal areas of orthokeratin are noted in the
luminal lining. Commonly, the flat basal layer may detach from its hemidesmosomal
attachment to the underlying connective tissue. The cyst lumen is commonly filled with
keratin debris on microscopic examination (6), clinically appearing as a cream of wheat
like solution which is visible if the cyst lining is ruptured on surgical removal.
KOTs have a relatively high rate of recurrence following surgical enucleation,
with studies noting a range of 5-62% (6). The thin cyst lining which is easily ruptured on
enucleation as well as propensity for satellite cysts are factors believed to contribute to
the high rate of recurrence. As a result, multiple surgical procedures have been described
for treatment of the KOT ranging from simple surgical enucleation to block resection.
Marsupialization or decompression followed by enucleation with peripheral ostectomy
has been shown to reduce the rate of recurrence while minimizing the risk of
neurosensory deficit or pathologic fracture when dealing with mandibular KOTs (17).
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2.3

Odontogenic Hamartomas
Hamartomas are developmental malformations of normal tissue. Odontogenic

hamartomas represent the most common odontogenic tumour; the odontoma is more
common than all other odontogenic tumours combined (6). Odontogenic hamartomas are
comprised of normal odontogenic tissue; enamel, dentin, pulp and cementum.

2.3.1

Odontoma
Fully developed odontomas consist primarily of dentin and enamel, remaining

stable in size and may erupt into the oral cavity (8). In early stages of development
odontogenic epithelium and mesenchyme remain surrounding the odontomas.
Odontomas are described as compound (multiple small toothlets) or complex (mass of
enamel and dentin, not in the shape of a tooth) (6). Largely asymptomatic, odontomas
are often found incidentally in the first two decades of life. Odontomas may present with
an unerupted tooth, or may be located between roots of teeth (6).
Histopathology of odontomas includes enamel and dentin, with variable amounts
of pulp and cementum. Multiple compound odontomas may present in a surrounding
fibrous stroma. Immature odontomas may present with odontogenic epithelium and
ectomesenchymal tissue surrounding the calcifying odontoma (6). Epithelial rests may
remain in the nearby tissue even after complete development of the odontoma.
Odontomas may be removed surgically when indicated.

2.4

Non-Odontogenic Maxillofacial Cysts
Non-odontogenic cysts of the head and neck fall primarily into the classification

of developmental cysts of the head and neck. These epithelial lined fluid filled cavities
increase as a result of increased hydrostatic luminal pressure (6). While a number of nonodontogenic cysts of the head and neck exist, only the nasopalatine duct cyst was studied
in this project, and as a result, will be discussed below.
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2.4.1

Nasopalatine Duct Cyst
The nasopalatine duct cyst, also known as the nasopalatine canal cyst or incisive

canal cyst is the most common non-odontogenic cyst of the maxillofacial region,
occurring in 1% of the population (6). This developmental cyst forms in the incisive
canal which is derived from the embryologic fusion of the premaxilla with left and right
palatal processes (11). Incisive canal contents include the nasopalatine nerve,
sphenopalatine and descending palatine arteries. In normal development, the epithelial
cells lining the nasopalatine duct degenerate, however in situations with incomplete
degeneration, epithelial remnants may give rise to the a nasopalatine duct cyst (6).
Possible etiologies of nasopalatine duct cyst development include spontaneous cystic
degeneration of contents of the nasopalatine duct, retention of mucous from minor
salivary glands, trauma and infection of the duct (6, 11).
Most commonly presenting in the 4th to 6th decades of life, nasopalatine duct
cysts are often discovered as incidental findings on routine intraoral radiography.
Alternatively, they may present as a swelling of the anterior maxilla/palate with or
without pain and drainage (6). The radiographic appearance consists of a well defined
radiolucency located between the maxillary central incisors.
Histopathology is variable, but diagnosis is made based on the presence of
pseudostratified ciliated columnar (respiratory) epithelium, simple columnar, cuboidal
and/or stratified squamous epithelium with or without neurovascular bundles and mucous
glands in the cyst wall (6, 8). Acute or chronic inflammation may be present in the cystic
wall. Malignant transformation has been reported but is very rare. Surgical enucleation
rarely results in recurrence.
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Chapter 3

3

Kallikreins
The past 30 years have resulted in a rapid expansion of knowledge of Kallikrein

physiology. The first kallikrein protein was identified in the 1930s as the most abundant
protease in the pancreas. It was subsequently named kallikrein for the Greek word for
pancreas (kallikreas) (18). Three classical human tissue kallikreins (kallikrein 1, 2 and 3)
were identified and their genes were localized in the 1980s. The 1990s and 2000s
resulted in the discovery of new kallikreins, resulting in knowledge of tissue kallikreins
1-15 as well as a pseudogene ψKLK1 (19, 20). In addition to human kallikreins have
been identified in a variety of animal species including monkeys, orangutans, mice, rats,
dogs, cats, horses, pigs, cows and elephants (21).
Human kallikreins can also been divided into a plasma kallikrein and several
tissue kallikreins based on their molecular biology and function. Tissue kallikreins are
encoded on chromosome 19 and are a group of contiguously encoded proteases. Unlike
the tissue kallikreins, the plasma kallikrein is encoded by a single gene (KLKB1) located
at chromosome 4q35and has no similarities to the tissue kallikrein genes. Plasma
kallikrein is secreted by hepatocytes as a plasma pre-kallikrein, an inactive precursor and
is activated to its mature form by factor XII in the coagulation cascade (22). Activation
of plasma kallikrein results in the release of bradykinin, with function in the coagulation
cascade, regulation of vascular tone and inflammation (22).

3.1

Human Tissue Kallikreins
Human tissue kallikreins (KLKs) are a group of 15 single chain serine proteases

with genes (KLK1-KLK15) encoded at chromosome 19q13.4 (23). The 15 KLKs
(numbered KLK 1- 15) constitute the largest group of contiguously encoded proteases in
the human genome (23). KLK1, KLK2 and KLK3 (prostate specific antigen or PSA) are
known as the classical kallikreins. KLK2 and 3 are the most closely related, sharing 80%
similarity at the amino acid and DNA level (21). Tissue kallikrein peptides are
represented with the short-form ‘KLK’ followed by their number (1-15), while their
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respective genes are noted with the abbreviation ‘KLK’. KLK 2-15 are officially named
“kallikrein related peptidases” while the KLK1 gene is known as Kallikrein 1 (24).
Tissue and Cellular Localization of Kallikreins
KLKs are expressed in a wide variety of human tissue types in normal and
pathologic states. Research has identified certain tissue types with high and low levels of
expression of specific KLKs in various tissues, as well as the presence of secreted KLKs
in biologic fluid such as seminal plasma, serum and milk (21). In addition to
identification of KLK mRNA in many different tissue types, multiple KLKs are often
expressed in single tissue types, such as the salivary glands, which express nearly all
KLKs (25). Multiple KLK mRNAs are also identified in the skin (KLK1, KLK4-11,
KLK13-14), prostate (KLK2-4, KLK11, KLK15), breast (KLK5-6, KLK10, KLK13),
pancreas (KLK1, KLK6-13) and central nervous system (KLK6-9, KLK14) (21).
Alternative KLK transcripts have been linked to specific tissue types; an example of this
includes splice variants of KLK2 and KLK3 which are identified exclusively in prostatic
epithelium (21). Localization of KLK has been studied largely utilizing
immunohistochemical analysis. KLK protein may be secreted, or sequestered to various
regions of the cell. KLK 5 and 7 are localized to the granular cell layer of normal skin,
KLK3, 4, 6, 7, 9, 10, 11, 13 and 14 are primarily found in the cytoplasm of glandular
epithelium (21).
Regulation of Kallikreins
KLK regulation occurs at multiple levels including at the post-translational,
transcriptional and post-transcriptional levels. Transcriptional control of KLKs occurs
through many avenues. In endocrine tissue, all KLKs appear to be controlled by steroid
hormones; steroid hormones and vitamin D receptors alter transcription of KLK genes in
other tissues as well (26). Steroid control of KLKs can occur via indirect and direct
mechanisms. Direct steroid transcriptional control occurs through the binding of steroid
hormone-receptor complexes to promoter/enhancer regions at ‘hormone response
elements’, which function by recruiting necessary cofactors to enhance transcriptional
activity. Indirect steroid transcriptional control functions through trans-acting
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transcription factors (21). Specific examples of steroid control include the upregulation of
KLK2 and KLK3 in response to progestin and androgen action in breast and prostate
cancer cell lines (21, 27). Androgen response elements have been identified in the
promoter region of KLK2 & 3. KLK4 is upregulated by estrogens in endometrial cancer
cell lines, and also upregulated by androgens in prostate cancer cell lines (21). It is
postulated that relative levels of activators/repressors contribute to the potential for up or
down regulation of transcriptional activity in each KLK (21, 27). Additional methods of
transcriptional control include epigenetic modifications including methylation and
histone modification (23). Methylation of an exon resulting in downregulation of KLK10
has been observed in acute lymphoblastic leukemia and breast cancer (21, 26).
Tissue kallikreins are translated as inactive precursors or zymogens, which have
pro-peptides physically blocking their active site. To be activated, the signal peptide, a
16-30 amino acid segment at the NH2 terminus is cleaved in the secretory pathway
resulting in the pro-KLK. Final activation often involves cleavage of 4-9 amino acid propeptides resulting in the active peptide (21, 26). KLKs can be activated by trypsin like
serine proteases, via endopeptidases or autocatalytic activation (21, 26).
Glycosylation of the KLK proteins is believed to be important for regulation of
proper KLK expression and function. KLKs and pro-KLK proteins have been identified
to be involved in kinin mediated signaling cascades such that variably expressed
kallikrein proteins can activate or inhibit expression of downstream kallikrein proteins
(20). As a result, multiple KLKs can be involved in one, or multiple signaling cascades
ultimately controlling biologic function. The roles of multiple KLKs acting on one
another and their respective zymogens has been described as the ‘KLK activome’, and
illustrates the complexity of the KLK family of proteins (26).
When activated, KLKs can be inactivated by a multitude of autolytic and
enzymatic methods (23). Kallistatin is an example of an endogenous inhibitor
responsible for the inactivation of KLK1 (26). KLK 6, 7, 13 and 14 have been shown to
be capable of autoinactivation in vitro (21). Serine protease inhibitors, known as serpins
are implicated in KLK inactivation via the ‘inhibitory pathway’. In this pathway, serpins
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such as protein C inhibitor (KLK2), α2-macroglobulin (KLK3, 5), α1-antichymotrypsin
(KLK3), antithrombin III (KLK6) and α2-antiplasmin (KLK5, 6, 13) produce complexes
that deform and irreversibly inactivate the various KLK proteins (21, 26). Local
physiologic conditions, including pH and the relative abundance of zinc can contribute to
reversible inhibition of KLKs (26). Plasmin has been identified to internally cleave
KLK11 resulting in its inactivation (26).
Through expression in these signaling cascades, as well as modification of KLKs
at the transcriptional, translational and post-translational levels of action, KLKs and their
proteins are capable of contributing to physiologic function and/or disease progression
(20).
Physiologic Roles of Kallikreins:
Kallikreins have been identified in a variety of tissues at the mRNA and protein
levels (21). Some tissues (such as salivary glands, skin and the central nervous system)
express multiple kallikrein proteins. As a result, KLKs have been investigated as
biomarkers, characterized for their relative abundance in disease states and investigated
for their roles in normal physiology. In general, five distinct methods of KLK mediated
cell signaling have been identified (28). These include the modulation of cell signaling
via the activation, generation or inactivation of peptide agonists from precursor proteins
(including hormones), the activation or inactivation of growth factor receptors (i.e.
tyrosine kinase growth factor receptors), cell signaling via extracellular matrix proteins
and integrins, the release of growth factor receptor agonists bound to cell membranes, as
well as the activation of proteinase activated receptors (i.e. G-protein coupled proteinase
activated receptors) (28). As a result of their ability to function in many different
pathways, KLKs can function in autocrine, paracrine and endocrine signaling utilizing
the proteinase activated receptor method of signaling (29). Specific examples of various
KLKs with resultant physiologic function will be described below.
KLK 1 is involved in the kinin-signaling cascade, cleaving low molecular weight
kininogen, releasing lysyl-bradykinin. The resultant binding of lysyl-bradykinin to target
receptors plays a role in modulating a wide variety of physiologic processes including
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blood pressure regulation, smooth muscle contraction, vascular permeability,
inflammatory cascades, neutrophil chemotaxis and pain induction (21, 23). These kinin
mediated processes are especially vital in pregnancy, when the KLK 1 mediated cascades
are involved in the control of placental blood flow, cellular proliferation and trophoblast
invasion (21). KLK 1 has been implicated in additional physiologic processes unrelated
to the kinin cascade. These include the activation of proinsulin to insulin and the
processing of growth factors (21). KLK 1 has been identified to have a protective effect
against lupus and antibody induced nephritis (30) and may play a role in calcium
homeostatic regulation (26). KLK 2 and 3, the remaining classical kallikrein proteins
also have well-established physiologic roles. KLK3/PSA is the most widely known
kallikrein as a result of utilization in monitoring prostate cancer (26). Seminal clot
liquefaction and subsequent sperm motility is partly controlled by KLK 2 and 3 through
the action of these kallikrein proteins hydrolyzing seminogelin I, II and fibronectin after
ejaculation (31, 32). KLK 3 functions more efficiently in the cleavage of the
aforementioned substrates. Activation of KLK 3 is dependent on a reduction in the high
concentration of zinc found in seminal fluid, which occurs through binding of zinc to
seminogelin I and II (26). KLK 2 may also contribute to the activation of KLK 3 in
prostatic tissue (33). Additional physiologic KLK 3 substrates include lysozymes and
growth factor binding proteins (21).
KLK 4 has been studied for its role in the formation of normal tooth enamel, a
process known as amelogenesis where it functions to degrade enamel proteins (34).
Research in porcine and mouse models suggests the role of KLK 4 in enamel matrix
processing during amelogenesis (21, 34). KLK 4 has been found to be secreted and
expressed by murine ameloblasts (34). A mutation in the KLK4 gene has been identified
in some patients suffering from one form of amelogenesis imperfecta, a disorder of
abnormal enamel formation (23, 35). Primary teeth from humans with KLK 4 mutation
exhibit opaque enamel deposition in comparison to control enamel. KLK 4 deficiency
results enamel with excess protein, abnormal crystal growth, but normal crystal
orientation, prism orientation and enamel thickness (36). Furthermore, in KLK4 null
mice and humans with mutations in the KLK4 gene, defects are noted in enamel, but not
elsewhere in the body (34). Using quantitative PCR, KLK 4 was also identified in
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prostate, adrenal, thyroid and salivary gland tissue (34). In these tissues, the physiologic
role of KLK 4 has not been determined.
KLK 5, 7 and 14 have been identified in the granular cell layer of the epidermis
and are found to degrade epithelial desmosomes (21, 26). KLK 5 possesses the ability to
auto-activate, and is implicated as a common activator (along with matrix
metalloproteases and urokinase-type plasminogen activator) in a number of KLK
signaling cascades; it has been demonstrated to activate pro-KLK 2, 3, 6, 7, 11, 12 and 14
(21, 26). Through the activation of KLK 7 and 14 by KLK 5, epithelial adhesion proteins
desmoglein, corneodesmin and desmocollin (located in the stratum corneum), can be
broken down to facilitate normal epithelial turnover. KLK 14 has been implicated in a
feedback loop in this epithelial turnover, and as a result, is involved in the skin
desquamation cascade through two effects of the protein (21, 26). KLK 5 and 7 also
contribute to the antimicrobial property of skin through their activation of human
cathelicidin precursor protein CAP18, activating cathelicidin to its mature form, which
possesses these antimicrobial properties (23, 26).
KLKs have been identified in other locations of a variety of other tissue types.
KLK 5, 6, 7, 8, 10, 11, 12 and 13 are present in cervicovaginal fluid in very high
concentrations. It is postulated that they may be involved in the desquamation of vaginal
epithelium, and possibly may have roles in processing of antimicrobial peptides found in
vaginal fluid (26). Immunohistochemical investigation has demonstrated the presence of
KLK 3, 4, 6, 7, 9, 10, 11, 13 & 14 in the cytoplasm of glandular epithelium (21). In
addition to KLK 5, KLK 2, 6 and 13 are also capable of autoactivation (21). In vitro
studies have identified the potential of KLK 3, 5, 6, 13 and 14 to cleave extracellular
matrix proteins, implicating them in tissue remodeling (21). KLK 6 is produced by
oligodendrocytes, and is involved in normal remyelination and the maintenance of
normal neuronal myelination through the cleavage of myelin basic protein (29).
Additional physiologic processes with KLK involvement include smooth muscle
contraction, neutrophil chemotaxis, inflammation, angiogenesis and pain induction (23).
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Kallikreins in Pathologic States:
Overexpression of some KLKs is found in malignant and non-cancerous disease
states. Studies have focused on the abundance of KLK in serum, identification of KLK in
tissue via immunohistochemistry and identification of relative levels of KLK mRNA.
The mechanisms resulting in altered KLK expression have not been well described for
many disease states. In addition, the exact pathway by which altered KLK expression or
altered KLK protein levels contribute to disease states is not always clear. Despite this,
some mechanisms of carcinogenesis including tumour growth, angiogenesis and invasion
have been correlated with altered KLK expression (21). Synergistic effects of kallikrein
proteolytic cascades where there is increased co-expression of multiple KLKs may result
in increased tumour growth compared with expression of unique KLKs alone (23).
Additionally, KLK overexpression has been identified as a prognostic marker in
malignancy (21). The following paragraphs will address some of the known changes in
KLK biology in pathologic states.
Kallikrein proteins have been identified to inhibit or promote carcinogenesis
depending on their expression. KLK 2, 3, 5, 6, 13 and 14 are known to directly catalyze
the breakdown of extracellular matrix (ECM) proteins, subsequently contributing to
direct tumour invasion, as well as potential metastasis (21). Indirectly, KLK 2 and 4 can
promote invasion and metastasis through the activation of urokinase type plasminogen
activator, which activates plasminogen to degrade ECM proteins (37, 38). In the prostate
KLK 3 also indirectly promotes tumour invasion and metastasis through the activation of
insulin like growth factor and activation of transforming growth factor beta (TGF-β).
TGF-β promotes invasion through cell detachment, and insulin like growth factor is
mitogenic for prostatic stromal and epithelial cells (39). Through its kinin activity, KLK
1 promotes an increase in vascular permeability, regulates angiogenesis, and supports
proliferation of tumour cells (21). Wolf et al (40) identified a synthetic inhibitor of
KLK1 that suppressed the invasive potential of breast cancer cell lines in vitro.
KLK 4, 5, 6, 7 and 15 mRNA expression and KLK 5, 6, 7, 10 protein expression
has been identified as a negative prognostic marker in ovarian cancer (21). In contrast,
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KLK 8, 9, 11, 14 expression and KLK 13 expression have been identified as favourable
prognostic markers in ovarian cancer (21). Splice variants or alternative transcripts of
KLKs have been identified in various forms of malignancy/disease. In ovarian cancer,
overexpression of KLK 5 and KLK 7 splice variants has been observed compared to
normal ovarian tissue (41). In addition, a unique KLK 8 variant was identified in ovarian
cancer tissue, and not identified in normal ovarian cells (42).
Observations of KLK expression in breast cancer provide other interesting
observations about KLK biology. KLK 6 is upregulated in primary breast tumours, but
down regulated at metastatic breast cancer sites (43). Additionally, levels of KLK 5 and
14 in serum of breast cancer patients were elevated, while the KLK 5 and 14 mRNA
expression was reduced in tissue (44, 45). KLK 3, 10, 12, and 13 mRNA are also
downregulated in breast cancer cell lines or tissues (21). KLK 10 is considered a tumour
suppressor gene and when injected into breast cancer cell lines, tumour formation in nude
mice was decreased (21). Downregulation of KLK 10 in breast, ovarian, prostate and
acute lymphoblastic leukemia is attributed to hypermethylation of exon 3 (46, 47).
Epigenetic modifications may also be responsible for other alterations in KLK expression
in disease states.
KLK 3 levels have been identified to be elevated in serum prostate cancer
patients, while decreased in tissue (21). It is postulated that the
malignancy/carcinogenesis, with associated angiogenesis and/or the loss of normal
glandular architecture contribute to an increased release of various KLKs from tissue,
resulting in an increased serum level. In prostate cancer bony metastasis may be
mediated by KLK 4; in vitro studies demonstrate that KLK 4 improves prostate cancer
cell migration against osteoblast secreted factors (48). mRNA quantification reveals that
KLK 2, 3, 5, 6, 10 and 13 are down-regulated, while KLK 11, 14 and 15 are
overexpressed in prostate cancer (21). In addition to its role as a serine protease, in
prostate cancer cell KLK3 produces reactive oxygen species (26).
Other malignancies identified to have aberrant KLK gene expression include lung
adenocarcinoma where KLK 11 is overexpressed in tumour of neuroendocrine origin,
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pancreatic adenocarcinoma where overexpression of KLK 10 is observed and acute
lymphoblastic leukemia where KLK 10 is downregulated (21). Utilizing
immunohistochemical evaluation, KLK 10 levels were found to be decreased in
pleomorphic adenoma specimens compared to normal salivary gland tissue (49). KLK 8
was found in normal and pathologic salivary gland tissue, and increased levels of KLK 8
were identified in mucoepidermoid carcinoma as well as adenocarcinoma NOS (50).
Normal salivary gland tissues, as well as multiple benign and malignant tumour types
were identified to have KLK 14 expression using immunohistochemical analysis.
Pleomorphic adenoma and adenoid cystic carcinoma tissues were identified to have
higher levels of KLK 14 relative to normal salivary gland control, as well as other
tumours investigated (51).
Benign disease states involving the neurologic, dermatologic and respiratory
systems are correlated with altered KLK expression. KLK 6 is found secreted by mouse
inflammatory cells in the central nervous system where it is understood to cleave basic
myelin proteins (29). KLK 1 and 6 are found to cleave alpha-synuclein, a large
component of the insoluble protein found in Lewy bodies, part of the underlying
pathology for Parkinson’s disease and Lewy body dementia (29). Uncontrolled
activation of KLK 5, 7 & 14 is identified to be a cause of over desquamation of skin in
peeling skin syndrome (23). KLK 7 may be involved in additional skin pathoses
including psoriasis, and inflammatory reactions due to the involvement of KLK 7
activating pro-inflammatory interleukins (21). Netherton syndrome is a genetic disorder
characterized by a mutation in the SPINK5 gene which is responsible for coding for the
serine protease inhibitor kazal type 5. The aforementioned mutation results in patients
suffering from the uninhibited proinflammatory effects of KLK 5 and 7 which signal via
proteinase activated receptors to contribute to the dermatologic abnormalities observed in
this syndrome (28). KLK 1 is the principle kinin generating enzyme of the human
airways and is implicated in bronchoconstriction, production of mucous and mediation of
vascular permeability (29, 52).
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Table 3.1 – Known or Proposed Roles as well as Association of KLK Protein and
KLK genes in Physiologic and Pathologic States
Known or Proposed Role or
Association

Kallikrein Protein or Gene
(KLK in Italic Font)
Associated

Refererence

Regulation of Blood Pressure, Smooth
Muscle Contraction, Inflammatory
Cascades

KLK 1

21, 23, 26, 30

Regulation of angiogenesis, vascular
permeability, support of tumour cell
proliferation

KLK 1

21,23, 26

Semen Liquefaction

KLK 2, 3 6, 7, 8, 14

26, 31, 32, 33

Skin Desquamation/Epithelial Turnover

KLK 5, 6, 7, 8, 10, 13, 14

21, 26

Desquamation of Vaginal Epithelium,
Antimicrobial Effect of Vaginal Fluid

KLK 5, 6, 7, 8, 10, 11, 12, 13

26

Antimicrobial Activity of Skin

KLK 5, 7

21, 23, 26

Extracellular Matrix Remodelling

KLK 3, 5, 6, 13, 14

21

Tumour Invasion via Direct Extracellular
Matrix Degradation

KLK 2, 3, 5, 6, 13

21

Activation of Urokinase Type
Plasminogen Activator (results in Tumour
Invasion)

KLK 2, 4

37, 38

Tumour Invasion via TGF-Beta and IGF
Activation

KLK 3

39

Amelogenesis

KLK 4

21, 34, 35, 36

Pro-Hormone Activation (i.e. of Insulin,
Growth Hormone, Glucagon,
Somatostatin, Pancreatic Peptides)

KLK 1, 3, 6, 10, 13

21

Myelination & Synaptogenesis

KLK 6, 8

29

KLK Autoactivation

KLK 2, 5, 6, 13

21

Favourable Prognostic Marker in Ovarian
Cancer

KLK 8, 9, 11, 14

21

KLK 13

28

Negative Prognostic Marker in Ovarian
Cancer

KLK 4, 5, 6, 7, 15

21

KLK 5, 6, 7, 10
Breast Cancer

Elevated serum KLK 5 & 14

21, 44, 45

Decreased KLK 5, 14
expression in breast cancer
tissue
Downregulated KLK 3, 10, 12,
13
Tumour Suppressor Gene (in Breast
Cancer cell lines)

KLK 10

21

Prostate Cancer

Improved bony metastasis –
KLK 4

21, 26, 48

Down regulated KLK 2, 3, 5,
6, 10, 13
Overexpressed KLK 11, 14, 15
Lung Adenocarcinoma

Overexpression KLK 11

21

Pancreatic Adenocarcinoma

Overexpressed KLK 10

21

Mucoepidermoid Carcinoma,
Adenocarcinoma NOS

Increased KLK 8

50

Pleomorphic Adenoma, Adenoid Cystic
Carcinoma

Increased expression KLK 14

51

Normal Salivary Gland

KLK 8, 14

50

Psoriasis

KLK 7

21

Bronchoconstriction

KLK 1

29, 52

Peeling Skin Syndrome

KLK 5, 7, 14

23

Parkinson’s Disease

KLK 1, 6

29
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Kallikreins as Biomarkers:
Biomarkers are useful in medicine for screening, diagnosis, prognosis, staging
disease and following disease after treatment. Kallikrein proteins have been used as
biomarkers for 3 decades, originally with the identification of serum KLK 3 (Prostate
Specific Antigen) and its association with prostate cancer. Due to their genetic similarity,
and relative physiologic abundance, KLK level and KLK expression have been
investigated in a number of additional disease states for their roles as serum or tissue
biomarkers (18).
Limitation of the specificity of the serum PSA has resulted in the utilization of
specific logarithmic regression models comparing KLK 2 to free PSA as well as free PSA
to total PSA in order to improve the diagnostic accuracy of biomarkers for prostate
cancer compared to benign prostatic hypertrophy (18). Additionally, expression of KLK
5, 11, 14 and 15 may correlate with Gleason biopsy grade, allowing the gene expression
level to act as a prognostic marker in prostatic carcinoma (18, 20). Utilization of KLKs
with additional serum markers has also been found to increase the diagnostic accuracy in
detection of prostate cancer. Utilizing an analysis involving free PSA, KLK 11,
migration inhibitory factor and macrophage inhibitor cytokine 1 improves the ability to
identify prostate cancer from benign prostatic hypertrophy (53). In testicular cancer,
KLK 5 expression has been correlated with improved outcomes and therefore may
represent a positive prognostic marker (20).
Identifying certain KLKs in ovarian and breast cancer aids in establishing the
diagnosis, as well as with prognosis (23). KLK 6 is associated with late stage, high grade
ovarian cancer. In addition, KLK 4, 5, 6, 7, 10 and 15 may correlate with poor prognosis
in ovarian malignancy (18, 20, 21, 23). KLK 8 and 14 may represent favourable
prognostic markers in ovarian cancer. Expression of KLK 4, 5, 6, 7 and 15 mRNA has
been identified as a negative prognostic marker, and KLK 4 may predict resistance to
paclitaxel chemotherapy, and may be therefore useful in guiding treatment (54). In
contrast, KLK 8, 9, 11 and 14 expression and KLK 13 expression have been identified as
favourable prognostic markers in ovarian cancer (21). To aid with pathologic diagnosis
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of primary ovarian malignancy versus metastatic disease, the presence of KLK 8, 10, 13
and Cancer Antigen 125 (CA 125) have been found to be superior to CA 125 alone (18).
Breast cancer investigation has revealed that increased expression of KLK 3, 9, 13 and 15
may indicate favourable prognosis while expression of KLK 5, 7 and 14 represent poorer
prognosis (18, 20). While still under investigation it is possible that expression of KLK 3
and 10 may predict response to tamoxifen therapy (20).
Additional malignancies where KLK levels or KLK expression may be of clinical
benefit include renal cell carcinoma, where KLK 6 expression is negatively correlated
with disease free survival (18). KLK 6 has been identified to be upregulated in
pancreatic, esophageal and gastric cancer; in these malignancies it carries with it an
unfavourable prognosis (18, 20). KLK 7, 8, 12, 13 and 14 have been identified as
potential serum markers for lung cancer. In neuroendocrine type lung cancer,
upregulation of KLK11 has been linked with worse outcomes (55).
Evaluation of epigenetic modifications such as methylation of kallikrein genes
may also prove beneficial in the evaluation of pathologic states. Methylation of KLK10
has been associated with a poorer prognosis and increased chance of relapse in acute
lymphoblastic leukemia (18).
Following their roles as biomarkers, the wide array of physiologic roles displayed
by KLKs in multiple tissue types has led to interest in targeting KLK expression/activity
for therapeutic intervention.
Possible Therapeutic Approaches Utilizing Kallikreins:
In addition to their role as biomarkers, kallikrein proteins and KLK expression are
potential therapeutic targets to alter disease progression. Inactivation of KLKs may
occur through cleavage (including auto-inactivation) and via serine protease inhibitors
(known as serpins). A single serpin may inhibit multiple proteases (KLKs), and each
protease can potentially be targeted by multiple inhibitors. Serpins work through
‘inhibitory’ and ‘substrate’ pathways. The inhibitory pathway results in formation of a
complex that irreversibly deforms the protease. Substrate inactivation is reversible, and
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occurs through preventing interaction of the proteases with potential substrates as a result
of steric hindrance (21). KLK inhibitors have been identified for KLK 1, 3 and 7 but the
biologic significance of these inhibitors is not yet fully understood (29). Therapeutic
approaches may take advantage of tissue specific expression of KLKs. Development of
pro-drugs with KLK specific peptide sequences could allow clinicians to minimize
systemic exposure of the drug, and maximize the local tissue exposure to areas of high
expression of the desired KLK (29). Development of specific KLK aptamers may
provide another option for therapeutic intervention of KLK mediated disease processes.
Proteinase activated receptors are known to be involved in signaling for a number
of dermatologic disorders (28) and may provide a potential avenue for therapeutic
intervention. Modification of the KLK – proteinase activated receptor pathway could
potentially help maintain skin homeostasis in disorders such as Netherton syndrome,
peeling skin syndrome type B, psoriasis, rosacea and atopic dermatitis (28, 29).
Neuropathologies are another broad category of diseases that could benefit from
KLK specific interventions. KLK8 deficient mice have been identified not to show
anxiety in response to stress provoking conditions (29). Intranasal administration of
recombinant KLK 1 reduces the rate of degeneration of the substantia nigra in a mouse
model of Parkinson’s disease (29). Targeting KLK 6, with a resultant blockage of KLK 6
activity in rodents delayed the onset and reduced the severity of the rodent model of
multiple sclerosis (29). Monoclonal antibodies are a potential method of delivering some
of these anti KLK 6 actions; in a mouse model, treatment with anti KLK6 neutralizing
antibodies resulted in a decrease in the loss of basic myelin protein and a delay in the
progression of the demyelination (56). Monoclonal antibodies developed to act as a
competitive inhibitor to KLK 1 have also been efficacious in a sheep model at reducing
bronchoconstriction and airway hyper-responsiveness; a potential therapeutic approach
for reactive airway disease (52).
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Chapter 4

4

Hypothesis and Rationale

4.1

Hypothesis
We hypothesize that human kallikrein proteins 3, 4, 5, 9 and 11 are expressed in

the following odontogenic tumours and cysts; ameloblastoma, KOT, dentigerous cyst and
lateral periodontal cyst. In this study we expect to find altered levels of kallikrein
proteins in the odontogenic cysts and tumours selected compared to our control tissues,
an odontogenic hamartoma (odontoma) and non-odontogenic maxillofacial cyst
(nasopalatine duct cyst). Additionally, we hypothesize that multiple KLK genes will be
expressed in ameloblastoma tissue samples and that the expression of KLK genes will
correlate with KLKs identified utilizing immunostaining.

4.2

Rationale
Odontogenic, non-inflammatory maxillofacial cysts and tumours vary greatly in

their ability to grow and cause local tissue destruction. Despite their common
embryologic origin, the biologic mechanisms responsible for this diverse array of clinical
behaviour are largely unknown. While the natural history of these neoplasms is known,
treatment strategies remain controversial for the KOT and ameloblastoma. Management
strategies for these cysts and tumours depend on the histologic diagnosis made from
biopsy specimens. Unfortunately, even with accurate tissue diagnosis and appropriate
surgical management, these tumours have relatively high recurrence rates (6, 7). While
this may be related to surgical technique, it may also be due to intrinsic tumour biology.
Additionally, there are no proven medical management strategies for these tumours, and
only some of these lesions lend themselves to minimally invasive surgical techniques
such as marsupialization. Due to their location in the facial skeleton, tumours causing
significant local tissue destruction can be quite disfiguring, leading to altered physical
appearance and oral function following their resection and surgical reconstruction(7). As
a result, a greater understanding of the molecular mechanisms responsible for the varied
clinical behaviour of these tumours would help improve our understanding of their
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biology. Furthermore, creating a profile of the proteins present or genes expressed in each
tumour or cyst may provide pathologists with a tool to assist in histopathologic diagnosis.
The ultimate goal of establishing biomarkers for these odontogenic cysts and tumours
would ideally be to provide clinicians an avenue to diagnose these neoplasms without
tissue biopsy or to allow analysis of the intrinsic features of each patient’s tumour to help
predict recurrence, therefore guiding treatment. With an improved understanding of the
tumour biology, it may be possible to develop strategies for medical or minimally
invasive management of these neoplasms.
Kallikrein proteins have been evaluated as biomarkers, investigated for their role
in molecular signaling cascades in multiple tissue types, and have been implicated in
tumour growth, angiogenesis, invasion and metastasis. Our lab has experience in the
investigation of head and neck neoplasms of salivary and odontogenic origin for the
presence and relative abundance of kallikrein proteins (25, 49, 50).

4.3

Aims and Objectives
This study aims to provide additional information on the pathogenesis and

increase the spectrum of diagnostic markers available for evaluation of odontogenic
maxillofacial neoplasms and cysts. Utilizing immunohistochemistry, we will investigate
the presence and relative abundance of KLK 3, 4, 5, 9 and 11 in odontogenic epithelium
including basal layer cells, clear cells, preameloblasts, stellate reticulum-like cells,
squamous cells and parakeratin in tissue from the following odontogenic tumours and
cysts; ameloblastoma, KOT, dentigerous cyst, lateral periodontal cyst, odontogenic
hamartoma (odontoma) and non-odontogenic maxillofacial cyst (nasopalatine duct cyst).
Reverse transcription – polymerization chain reaction (RT-PCR) will be used to
evaluate for the presence of mRNA for the 15 human kallikrein proteins in
ameloblastoma tissue. We will then compare the mRNA expression with the KLK
protein identified utilizing immunohistochemistry (where possible) based on data from
our laboratory. Using this data, we will evaluate whether altered expression and/or
unique KLK profiles help to predict behaviour of these lesions.
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Chapter 5

5

Materials and Methods

5.1

Materials for Immunostaining
Tissue samples for the tumours, cysts and control tissues were obtained from the

division of Oral Pathology, Schulich School of Medicine and Dentistry, Western
University and London Health Sciences Centre. Multiple hematoxylin and eosin stained
slides of each tissue type were assessed by the graduate student (KC) as well as two
experienced oral and maxillofacial pathologists to determine if sufficient lesional tissue
was present for immunostaining purposes. Ultimately, sixty (n=60) formalin fixed
paraffin embedded specimens were selected for investigation from the archives of the
Division of Oral Pathology. These included lateral periodontal cysts (n=9), dentigerous
cysts (n=10), KOTs (n=11) and ameloblastomas (n=11) as well as nasopalatine duct cysts
(n=9, non-odontogenic cystic control) and odontomas (n=10, hamartoma as neoplasm
control). Patient demographics including age, sex, and site of lesion are noted in tables
5.1 – 5.6.
Table 5.1 – Lateral Periodontal Cyst Tissue Demographic Information
Case Number
1
2
3
4
5
6
7
8
9

Age
84
61
75
79
70
62
58
59
80

Sex
Female
Female
Male
Female
Male
Female
Male
Female
Female

Site
Anterior mandible
Anterior mandible
Left maxilla premolar area.
11,21 area
Left mandible
Left mandible 34 area
Right mandible 43/44
Left mandible
44/45 area
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Table 5.2 – Dentigerous Cyst Tissue Demographic Information
Case Number
1
2
3
4
5
6
7
8
9
10

Age
48
40
40
43
55
26
45
49
50
32

Sex
Male
Female
Female
Male
Female
Female
Male
Male
Male
Male

Site
impacted 48
Impacted 38
impacted 48
impacted 48
impacted 48
Impacted 38
Impacted 38
impacted 48
impacted 48
impacted 38

Table 5.3 – Keratocystic Odontogenic Tumour Tissue Demographic Information
Case Number
1
2
3
4
5
6
7
8
9
10
11

Age
34
32
71
19
64
44
46
57
67
20
52

Sex
Male
Female
Male
Female
Male
Male
Male
Male
Male
Male
Male

Site
Right mandible 48 area
Left posterior mandible.
Mandible 33 and 35 area
Left ramus
Right mandible 46 area
Right mandible
Mucosa between 27 and 24
Left body and ramus manidble
Maxilla 24 area
Left mandible 38 area
Left maxilla 24/25

Table 5.4 – Ameloblastoma Tissue Demographic Information
Case Number
1
2
3
4
5
6
7
8
9
10
11

Age
82
74
35
55
51
75
15
75
52
57
26

Sex
Female
Male
Female
Male
Female
Female
Female
Female
Male
Male
Female

Site
Lingual to 31 to 42.
Left anterior mandible
Left posterior mandible
Left ascending ramus
Left mandible
Maxilla/sinus
38 area
Right maxillary sinus
Right mandible 46 area
32/33 area
35 area
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Table 5.5 – Nasopalatine Duct Cyst Tissue Demographic Information
Case Number
1
2
3
4
5
6
7
8
9

Age
81
32
78
53
12
67
59
38
35

Sex
Male
Female
Male
Male
Male
Female
Male
Female
Male

Site
Right maxilla 11 area
11,21 area
Incisive canal
Anterior maxilla
Anterior maxilla 11/21
Anterior maxilla
Right anterior maxilla
Anterior maxilla
Maxillary midline

Table 5.6 – Odontoma Tissue Demographic Information
Case Number
Age
COMPLEX ODONTOMA
1
29
2
19
3
18
4
18
5
10
6
7
7
13
8
17
COMPOUND ODONTOMA
9
17
10
11

Sex

Site

Female
Female
Female
Male
Female
Female
Male
Female

Maxilla 22/23 area
Left posterior maxilla
Mandible 38 area
Maxilla 28 area
Maxilla 16 area
Right mandible 85 area
Left mandible apical to 73
Left maxillary tuberosity

Male
Female

Left mandible 32/33 area.
Right anterior maxilla
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Table 5.7 – Patient Demographics for Study Lesion Population
Lesion Type

Number of

Mean Age

Gender

Specimen

(years)

(Male:Female)

Lateral Periodontal Cyst

9

69.8

3:6

Dentigerous Cyst

10

42.8

6:4

Keratocystic Odontogenic

11

46.0

9:2

Ameloblastoma

11

54.3

4:7

Nasopalatine Duct Cyst

9

50.6

6:3

Odontoma

10

15.9

3:7

Tumour

Summary data outlining number of specimens investigated, mean age, and gender
distribution are indicated in table 5.7
Diagnosis of the lesion was based on the World Health Organization classification
of tumours (57). Evaluation of 10-11 lesions per tissue type was planned, but for
nasopalatine duct cysts and lateral periodontal cysts there was insufficient tissue in some
cases.
Positive staining control tissue was obtained based on known expression of KLK
3, 4, 5, 9 and 11 in various human tissue types (Table 5.8) (18-21, 23, 26, 29, 34, 45, 48).
Positive control tissues were used to determine optimal antibody concentration, and as a
result, appropriate staining intensity utilizing graded concentrations of antibody and the
staining method described in the following section of text (5.7). Antibody dilutions are
outlined in table 5.8
Evaluation of KLK 3, 4, 5, 9 and 11 in the tumours, cysts and control tissues were
performed utilizing a standard immunohistochemical staining technique.
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5.2

Methods for Immunostaining
Parrafin embedded tissue samples were cut into 5 µm thick serial sections using a

microtome (Microm HM 325;GMI Inc., Ramsey, MN) then transferred to a water bath at
45°C. After mounting these sections on positively charged glass slides, they were dried
overnight in an incubator at 37°C. Following this, slides were treated with xylene
followed by ethanol dilutions then water. A 3% hydrogen peroxide in methanol solution
was then used, and rinsed with distilled water and phosphate buffered saline (PBS) on a
shaker. Antigen retrieval was performed using a pH 6.0 citrate buffer in a de-cloaking
chamber. Slides were then rinsed and blocked using 10% horse serum. Incubation was
next performed with the primary antibody as described in table 5.8. Excess antibody was
then removed using a PBS rinse, and slifes were incubated utilizing the ImmPRESS®
kit’s (ImmPRESS® Reagent Kit; Vector Laboratories, Burlingame, CA) anti-appropriate
antibody horse-radish peroxidase micro polymer solution. Slides were rinsed and then
stained with Diaminobenzidine (DAB) solution (Vector Laboratories, Burlingame, CA).
Counterstaining was performed utilizing hematoxylin and slides were then dehydrated
using ethanol and xylene in series. Slides were then mounted and cover slips were
applied utilizing Cytoseal® (VWR, Mississauga, ON).
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Table 5.8 - Antibody and Incubation Protocol for Immunostaining
Kallikrein
Protein

Antibody Used

KLK 3

Rabbit

Antibody Titre

Positive
Control
Tissue

Incubation

1/800

Prostate

Overnight at
4oC

1/600

Prostate

Overnight at
4oC

1/800

Seborrheic
Keratosis

1 hour at Room
Temperature

1/100 = 10 ug/mL

Prostate

Overnight at
4oC

1/200 = 5 ug/mL

Prostate

1 hour at Room
Temperature

(µL antibody/µL
HS)
(polyclonal)

KLK 4

Rabbit
(polyclonal)

KLK 5

Mouse
(monoclonal)

KLK 9

Goat
(polyclonal)

KLK 11

Mouse
(monoclonal)

5.2.1

Evaluation of Immunostaining
Immunostained slides were evaluated under light microscopy utilizing a semi-

quantitative analysis previously described (25, 51). Cells evaluated for staining were the
odontogenic epithelium including basal layer cells, clear cells, preameloblasts, stellate
reticulum-like cells, squamous cells and odontogenic parakeratin. Staining was evaluated
by two oral and maxillofacial pathologists as well as the graduate student author.
Staining intensity and proportion of cells stained were assigned non-parametric scores as
illustrated in Table 5.9 and 5.10. The staining intensity score and proportion of cells
stained scores were summed to yield an overall staining score (OSS) ranging from 0-8 for
each slide of tissue evaluated. An OSS was also generated for non-study, control tissue
used to assess the quality of immunostaining (i.e. prostate tissue control) for quality
control purposes. The average KLK overall staining score was then generated for each
tissue type and compared with all other tissue types within each KLK investigated.
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Table 5.9 - Staining Intensity Scoring System
Score

Staining Intensity

0

None

1

Weak

2

Moderate

3

Strong

Table 5.10 - Percentage of Cells Stained Scoring System
Score

Percentage of Cells Stained

0

0%

1

<1%

2

1-10%

3

10-30%

4

30-60%

5

>60%
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5.3

Materials for Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Formalin fixed, paraffin embedded ameloblastoma tumours were obtained from

the archives of the division of Oral Pathology at the Schulich School of Medicine and
Dentistry, Western University and London Health Sciences Centre and sectioned into 10
µm thick samples. The following lesional tissue sections were pooled; patient
demographic information is included in table 5.10.
Table 5.11 - RNA Obtained for Each Ameloblastoma Tumour Specimen
Formalin Fixed Ameloblastoma

Concentration RNA (at 1% RNA)

Tissue Case Numner

(ug/mL)

1

0.276

2

0.208

3

0.101

4

0.039

5

0.129

6

0.120

7

0.406

8

0.071

9

Insufficient RNA

10

0.885
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5.4

Methods for RT-PCR
Ten µm thick samples of each tumour were placed into 1.5 mL collection tubes.

The tissues were then deparaffinized by adding xylene. The samples were mixed and
centrifuged at 12000 xg for 2 minutes. Supernatant was discarded and the
deparaffinization steps were repeated 3 more times. Samples were then passed through
absolute ethanol and 70% ethanol, mixing and centrifuging (12000 xg for 2 minutes) for
each step. Next, total RNA was isolated from these deparaffinized samples using Roche
formalin fixed paraffin embedded RNA isolation kit (High Pure FFPE RNA Micro Kit;
Roche Applied Sciences, 2011, Mannheim, Germany, Catalogue number: 04823125001).
Briefly, tissue lysis buffer containing sodium dodecylsylphate was added to the tissue
pellets. Samples were then centrifuged and digested with proteinase K for 3 hours. RNA
was then isolated using High Pure RNA binding spin columns as recommended by the
manufacturer.
Total RNA was measured using Qubit® Quant-iT™ RNA BR Assay Kit and
Qubit® Fluorometer (Life Technologies). Nine out of ten ameloblastoma samples
produced sufficient RNA for use in the synthesis of cDNA; the quantity of RNA is noted
in Table 5.11. The 9 remaining ameloblastoma tissue samples were then pooled and
cDNA was generated using 4 µg of total RNA using the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories, Hercules, CA). KLK primers are listed in Table 5.12, with
specific catalogue number denoted for each primer. Reagents are noted in Table 5.13.
RT-PCR reactions were performed in BioRad CFX Connect (Bio-Rad Laboratories) and
comprised of 10 µL SYBR Advantage qPCR premix (Clontech Laboraories Inc.,
Mountain View, CA), 5.5 µL H20, 2.5 µL cDNA, and 2 µL of primer for each KLK.
Data was normalized to β-actin as a control/housekeeping gene. Reactions were
completed as follows: 95oC for 2 minutes (initial denaturation/activation), 95oC for 5
seconds, 62oC for 10 minutes for 40 cycles of amplification. Melting curve analysis was
performed to determine specificity of the reactions.
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Table 5.12 – PCR Gene Primers with Catalogue Information
Primer

Vendor

Catalogue Number

KLK 1

Qiagen

QT00020664

KLK 2

Qiagen

QT00088466

KLK 3

Qiagen

QT00027713

KLK 4

Qiagen

QT00495159

KLK 5

Qiagen

QT00010437

KLK 6

Qiagen

QT00013972

KLK 7

Qiagen

QT00028343

KLK 8

Qiagen

QT00017689

KLK 9

Qiagen

QT00057190

KLK 10

Qiagen

QT00039816

KLK 11

Qiagen

QT00011011

KLK 12

Qiagen

QT00067977

KLK 13

Qiagen

QT00029876

KLK 14

Qiagen

QT00039928

KLK 15

Qiagen

QT00035735

Beta Actin

Qiagen

QT01680476
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Table 5.13 – PCR Reagents
Reagent

Vendor

Catalogue Number

ssoFast Evagreen PCR Kit

Bio-Rad

172-5201

iScript™ Reverse Transcription

Bio-Rad

1708841

Supermix for RT-qPCR

5.5 Statistical Analysis
Mean overall staining scores and standard deviation of mean were calculated for
all tissue types for each KLK of interest. Non-parametric statistical analysis was
performed utilizing GraphPad software (GraphPad InStat version 3.00 for Windows 95,
GraphPad Software, San Diego, California, USA). Dunn’s multiple comparison test was
used to evaluate for significance within each KLK type, and the Kruskall-Wallis test was
utilized to examine for significance between overall staining scores of each tissue type
within each set of KLK stained. Significance level for all tests was p<0.05.
The standard curve method of RT-PCR analysis was used to assess relative levels
of KLK mRNA in the pooled ameloblastoma tissue. Since we wanted to confirm the
presence of KLK transcripts (indicating expression of KLK) in the samples, we pooled
the samples to yield PCR-quality cDNA. No statistical tests were performed due to the
lack of comparison with other control tissue.
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6

Results

6.1

Immunostaining
Representative images were obtained for KLK 3, 4, 5, 9 and 11 staining in the

control and study tissues. These images are displayed below (Figures 6.1 – 6.6) and were
taken at 100X original magnification unless otherwise indicated on the figure legend
where ‘50x’ represents an image taken at 50X original magnification. Mean and median
staining scores for all tissues stained are presented in tables 6.1 and 6.2. Figures 6.7 6.10 graphically depict the mean and median overall staining scores for KLK 3, 4, 5, 9
and 11 in the study tissues.
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Figure 6.1 - KLK 3 Immunostaining (indicated by brown stain in tissues)

Ameloblastoma

Keratocystic Odontogenic Tumour

Dentigerous Cyst

Lateral Periodontal Cyst

Nasopalatine Duct Cyst (50x)

Odontoma
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Figure 6.2 - KLK 4 Immunostaining (indicated by brown stain in tissues)

Ameloblastoma

Keratocystic Odontogenic Tumour

Dentigerous Cyst
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Figure 6.3 - KLK 5 Immunostaining (indicated by brown stain in tissues)
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Figure 6.4 - KLK 9 Immunostaining (indicated by brown stain in tissues)
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Figure 6.5 - KLK 11 Immunostaining (indicated in brown stain in tissues)
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Figure 6.6 - Control Immunostaining (indicated by brown stain in tissues)

Prostate (Control for KLK 3, 4, 9, 11) (50x) Sebhorrheic Keratosis (Control for KLK 5)
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Table 6.1 - Mean Values (+/- Standard Deviation) for Staining Intensity in
Odontogenic Cysts, Tumours and Controls
Tissue Type

KLK 3

KLK 4

KLK 5

KLK 9

KLK 11

Lateral
Periodontal Cyst

5.6 +/- 2.2

7.3 +/- 0.9

0

7.8 +/- 0.5

6.3 +/- 2.7

Dentigerous Cyst

4.9 +/- 2.6

7.4 +/- 0.5

0

7.9 +/- 0.4

6.9 +/- 0.6

6.0 +/- 0.6

7.5 +/- 0.5

2.7 +/- 2.2

7.7 +/- 0.5

6.6 +/- 0.5

6.5 +/- 0.7
3.5 +/- 2.7

7.5 +/- 0.7
6.1 +/- 3.4

0
0

6.9 +/- 0.3
6.3 +/- 2.2

7.3 +/- 0.6
5.1 +/- 2.7

5.4 +/- 0.7

7.6 +/- 0.5

0

7.3 +/- 0.8

5.7 +/- 1.1

Keratocystic
Odontogenic
Tumour
Ameloblastoma
Odontoma
Nasopalatine
Duct Cyst

Table 6.2 - Median Values for Staining Intensity in Odontogenic Cysts, Tumours
and Controls
Tissue Type

KLK 3

KLK 4

KLK 5

KLK 9

KLK 11

Lateral
Periodontal Cyst

6

8

0

8

7

Dentigerous Cyst

6

7

0

8

7

6

7

4

8

7

7
4

8
8

0
0

7
7

7
6

6

8

0

7.5

5

Keratocystic
Odontogenic
Tumour
Ameloblastoma
Odontoma
Nasopalatine
Duct Cyst
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Figure 6.7 - Mean Immunostaining Score Illustrated for Each Tissue Type Studied
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Figure 6.8 - Mean Immunostaining Score Illustrated for Each KLK Investigated
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Figure 6.9 - Median Immunostaining Score Illustrated for Each Tissue Type
Studied
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Figure 6.10 - Median Immunostaining Score Illustrated for Each Tissue Type
Studied
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6.1.1 Immunostaining Statistical Analysis
KLK 3, 4, 9 and 11 are identified through immunostaining in the Ameloblastoma,
KOT, Dentigerous Cyst, Lateral Periodontal Cyst, Odontoma and Nasopalatine Duct
Cyst. KLK 5 is only present in the KOT.
For KLK 3, the Kruskal-Wallis test reveals a p value of 0.004, showing
significant variance between the lesions investigated. The Dunn’s multiple comparison
test shows significantly more staining in ameloblastoma tissue than to odontoma (p<0.01)
and KOT than odontoma (p<0.05). No other statistically significant differences were
noted. No other statistically significant differences were identified.
Analysis of KLK 4 staining using the Kruskal-Wallis test reveals a p value of
0.5554, signifying no difference between groups investigated.
For KLK 5 the Kruskal-Wallis test revealed a p value of < 0.0001, identifying that
variation amongst the lesions is greater than can be expected by chance. Dunn’s multiple
comparison test reveals that p < 0.001 showing that KLK 5 was statistically significantly
more prevalent in the KOT than all other lesions investigated.
Analysis of KLK 9 staining using the Kruskal-Wallis test reveals a p value of
0.0002. This statistically significant difference was further evaluated using the Dunn’s
multiple comparison test which revealed more KLK 9 staining in the Dentigerous Cyst
than Odontoma (p<0.05), KOT than Odontoma (p<0.05), Lateral Periodontal Cyst than
Ameloblastoma (p<0.05), Dentigerous Cyst than Ameloblastoma (p<0.01), and KOT
than Ameloblastoma (p<0.05). No other statistically significant differences were
identified.
Analysis of KLK 11 staining using the Kruskal-Wallis test reveals a p value of
0.0025, showing that there is statistically significant variance amongst the study groups.
Dunn’s multiple comparison test reveals p<0.05 when comparing KLK 11 staining in the
Ameloblastoma and the Nasopalatine Duct Cyst; more staining is present in the
Ameloblastoma than the Nasopalatine Dyct Cyst. No other statistically significant
differences were identified.
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Table 6.3 – Statistically Significant Differences in Kallikrein Immunostaining
Kallikrein

Kruskal-Wallis

Protein

(Analysis of Variance)

KLK 3

P = 0.0040

Dunn’s Multiple Comparison Test
Ameloblastoma > Odontoma, p<0.01
KOT > Odontoma, p<0.05

KLK 4

P = 0.5554

No Difference

KLK 5

P < 0.0001

KOT > Odontoma, p<0.001
KOT > Nasopalatine Duct Cyst,
p<0.001
KOT > Ameloblastoma, p<0.001
KOT > Dentigerous Cyst, p<0.001
KOT > Lateral Periodontal Cyst,
p<0.001

KLK 9

P = 0.0002

Dentigerous Cyst > Odontoma,
p<0.05
Keratocystic Odontogenic Tumour >
Odontoma, p<0.05
Lateral Periodontal Cyst >
Ameloblastoma, p<0.05
Dentigerous Cyst > Ameloblastoma,
p<0.01
Keratocystic Odontogenic Tumour >
Ameloblastoma, p<0.05

KLK 11

P = 0.0025

Ameloblastoma > Nasopalatine Duct
Cyst, p<0.05
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6.2

mRNA Analysis
KLK 1, 4, 7, 8, 10 and 12 genes were identified using PCR for pooled

ameloblastoma tissue from nine of the ten tissue samples used for immunostaining.
Insufficient cDNA was produced to facilitate use for RT-PCR from the tenth
ameloblastoma tissue sample. KLK 1-15 were assessed using RT-PCR. KLK 2, 3, 5, 6,
9, 11, 13, 14 and 15 were not detected using the current study methods. Results were
calculated using the difference in cycle threshold (CT) (Table 6.4 and 6.5) as well as
standard curve (Table 6.6 and 6.7) methods of analysis. Using the standard curve
method, average relative mRNA levels were detected, and are depicted with associated
standard deviation in Figure 6.11.
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Table 6.4 – Raw PCR Data – Run 1 Change in CT Method
Gene

Ct 1

Ct 2

Ct Average

Concentration Relative
mRNA
Levels

KLK 1

48.81

51.97

50.39

19.10015

0.0000018

KLK 4

49.81

49.61

49.71

18.42137

0.0000028

KLK 7

39.81

39.71

39.76

8.47041

0.0028194

KLK 8

41.28

44.99

43.13

11.84467

0.0002719

KLK 10

32.72

32.36

32.54

1.25107

0.420136

KLK 12

43.35

42.59

42.97

11.68106

0.0003045

Beta-Actin

31.38

31.19

31.29

NA

NA

Table 6.5 - Raw PCR Data – Run 2 Change in CT Method
Gene

Ct 1

Ct 2

Ct Average

Concentration Relative
mRNA
Levels

KLK 1

41.88

45.91

43.89

14.88492

0.0000331

KLK 4

44.73

43.64

44.19

15.17644

0.0000270

KLK 7

38.25

37.24

37.74

8.73434

0.002348

KLK 8

43.24

43.49

43.37

14.35506

0.0000477

KLK 10

32.19

31.01

31.60

2.59312

0.165727

KLK 12

42.81

42.31

42.56

13.55115

0.000083

Beta-Actin

29.01

29.00

29.01

NA

NA
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Table 6.6 - Raw PCR Data – Run 2 Standard Curve Method
Gene

Ct 1

Ct 2

Ct Average

Concentration Relative
mRNA
Levels

KLK 1

41.88

45.91

43.89

23.38405

1.01015

KLK 4

44.73

43.64

44.19

19.36874

0.83669

KLK 7

38.25

37.24

37.74

57.08126

2.46581

KLK 8

43.24

43.49

43.37

28.97867

1.25183

KLK 10

32.19

31.01

31.60

56.78855

2.45316

KLK 12

42.81

42.31

42.56

29.46897

1.27300

Beta-Actin

29.01

29.00

29.01

23.14909

NA

Table 6.7 - Average Relative mRNA Levels
Gene

Relative mRNA Average

Standard Deviation

KLK 1

0.76961

0.34017

KLK 4

0.67650

0.22655

KLK 7

2.60676

0.19934

KLK 8

1.43129

0.25380

KLK 10

2.71217

0.36629

KLK 12

1.41314

0.19818
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Figure 6.11 - Relative Expression of KLK mRNA for KLK’s Detected in Pooled
Ameloblastoma Tissue

Relative KLK mRNA for Pooled
Ameloblastoma Tissue
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Chapter 7

7

Discussion

7.1

Expression of KLK 3, 4, 5, 9 and 11 in Maxillofacial
Cysts and Tumours
For the first time, Kallikrein Protein 3, 4, 5, 9 and 11 have been identified in oral

and maxillofacial cysts and tumours. KLK 3, 4, 9 and 11 were identified in odontogenic
and non-odontogenic cysts and tumours, while KLK 5 was identified only in the KOT.
Prior research from our lab has identified the presence of KLK 6, 7, 8, 10, 13 and 14 in
odontogenic cysts and tumours (58).
KLK 3 staining was significantly greater in the benign neoplasms of odontogenic
origin, the Ameloblastoma and KOT compared to odontogenic control, the Odontoma. In
the Ameloblastoma tissue, there was patchy staining of the connective tissue stroma,
consistent with KLK 3 being a secreted protein. Macrophage staining and stromal
staining were also present in the tissue surrounding the KOT. In the Odontoma
specimens, care was taken to ensure that staining was only counted when odontogenic
epithelial cells were visualized, as uniformly intense staining of enamel protein was
present in some specimens. The unique increased expression in the benign odontogenic
neoplasms (Ameloblastoma and KOT) suggests that KLK 3 may have a role in the
intrinsic and limitless growth potential of these lesions compared to less clinically
aggressive odontogenic cysts. KLK 3 has been identified to be involved in tumour
invasion by direct extracellular matrix degradation as well as tumour activation by TGFBeta and Insulin like growth factor (21). It may be that KLK 3 is involved in the growth
of these lesions through the aforementioned mechanisms and signaling cascades, or
through alternative mechanisms not yet identified. In the second series of experiments as
part of this thesis, KLK 3 mRNA was not identified in the Ameloblastoma when utilizing
RT-PCR for the pooled Ameloblastoma tissue. This suggests that KLK 3 protein may be
recruited to the Ameloblastoma where it was stained and identified microscopically. It
may similarly be recruited to the KOT, and/or other odontogenic lesions staining
positively for KLK 3, or the KLK 3 gene may actually be expressed in these
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tumours/cysts, resulting in intrinsic Kallikrein protein production. Alternatively, KLK 3
may have a very long half life, allowing it to be identified within the lesional tissue
stained while not identified using the RT-PCR assay utilized in this study due to minimal
abundance of the mRNA. Nonetheless, the presence of statistically significantly
increased KLK 3 protein in these tumours would be interesting to further investigate.
Studying this protein may contribute to an understanding of the more aggressive
behaviour observed in the Ameloblastoma and KOT compared to odontogenic cysts. Our
data and experimental design do not readily support any specific mechanism of action of
KLK 3, however potential roles could include KLK 3 acting as a part of a larger cascade
of molecular signaling involving other KLK proteins where it may function to permit
local tissue destruction resulting in extension/invasion of the lesion, or act in a cascade as
an activator of growth or as an inhibitor of growth suppression. The relatively wide
variety of physiologic processes and pathways of molecular signaling identified to be
associated with KLKs suggest that KLK 3 could be involved in the pathogenesis of these
lesions in many possible ways.
KLK 3 has been widely studied with respect to its role in urologic physiology,
and is known as a biomarker in prostate cancer. Levels of prostate specific antigen (KLK
3) are measured utilizing a serum assay, and followed in cancer surveillance. It would be
interesting to study the plasma levels of prostate specific antigen in individuals with
odontogenic cysts or tumours in women or men with no known prostate disease to see if
there are increased levels of serum PSA in these individuals. If PSA/KLK 3 was detected
in the serum of patients with odontogenic pathology, it may be prudent to screen
individuals being followed for prostate cancer for odontogenic pathology to ensure it
does not alter the post-cancer surveillance for these patients.
KLK 4 staining was prevalent in all study and control tissue. No significant
difference was noted between any of the groups analyzed. It was expected that KLK 4
would be present in all odontogenic tissues (Ameloblastoma, KOT, Dentigerous Cyst,
Lateral Periodontal Cyst and Odontoma) due to the known role of KLK 4 in
amelogenesis. The Nasopalatine Duct Cyst (non-odontogenic maxillofacial cyst)
surprisingly exhibited KLK 4 immunostaining with similar magnitude to that observed in
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the odontogenic tissues. In addition to its role in amelogenesis, KLK 4 has been
implicated in the activation of urokinase type plasminogen activator which can promote
tumour invasion through its action. In non-odontogenic tissue such as the Nasopalatine
Duct Cyst, KLK 4 may have a role in a signaling cascade involving other proteins,
possibly including other KLKs, or may be recruited to the site of the lesion and
sequestered. Qualitative observations made in the histopathologic analysis and scoring
include the fact that the Ameloblastoma tissue exhibits minimal staining in the stellate
reticulum compared to the cytoplasm of the lesional Ameloblasts and that enamel stains
significantly while dentin exhibits no staining in the Odontoma tissues when
investigating for KLK 4. As outlined previously, this was expected due to the known
role of KLK 4 in normal enamel maturation. As expected, KLK 4 mRNA was identified
using RT-PCR in the pooled Ameloblastoma tissue. It would be interesting to study
odontogenic and non-odontogenic pathologic lesions in patients with known KLK 4
mutation. While these individuals would be expected to have opaque, abnormal enamel
deposition, it would be interesting to see if KLK 4 was still recruited to the tumour/cyst
tissue, where it may function in an additional signaling cascade with proteolytic functions
apart from those in normal amelogenesis.
KLK 5 was only identified in the KOT. The KLK 5 staining was localized to the
parakeratin layer within the KOT and no KLK 5 staining was present in any of the
remaining tissue types investigated. It was not surprising to find KLK 5 localized to the
parakeratin of the KOT, as this parakeratinized cyst was the only pathology to be
investigated with keratin maturation. Despite the fact that no other tumours or cysts
identified produce a keratin layer, we were surprised that KLK 5 was not identified in any
other tissue types investigated as KLK 5 has been identified to be capable of
autoactivation, and is involved in multiple KLK signalling cascades. KLK 5 is identified
in the granular cell layer of the epithelium of the skin; therefore Seborrheic Keratosis was
utilized as a control tissue for staining. KLK 5’s role in the antimicrobial activity of skin,
normal epithelial turnover and in dermatologic disorders such as peeling skin syndrome
suggests that it is required for normal turnover of keratinized epithelium. It would be
interesting to investigate the Orthokeratinized Odontogenic Cyst for the presence of KLK
5, as it has similar histopathologic findings as the KOT, but without the parakeratin layer.
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It would also be beneficial to complete RT-PCR on KOT specimens in order to
investigate whether KLK 5 is produced intrinsically by the KOT/epithelium or whether it
is recruited to this site where it can then function in the normal desquamation of the
parakeratinized epithelium. In odontogenic tumours and cysts, it is unlikely that KLK 5
is involved in signaling cascades regulating tumour/cyst growth and behaviour due to the
fact that it is only expressed in the keratinized tumour, the KOT.
KLK 9 staining was present in all tissues studied. Significantly increased staining
was present for the Dentigerous Cyst compared to the Odontoma (odontogenic control)
and Ameloblastoma. Significantly increased staining was present in the KOT when
compared to the Odontoma and Ameloblastoma. The Lateral Periodontal Cyst also
exhibited significantly increased staining when compared to the Ameloblastoma. Nuclear
and cytoplasmic staining was noted in the Ameloblastoma tissue when staining for KLK
9. In the KOT specimens, generalized subepithelial staining was identified. Patchy
staining was visualized in the basal layer of the Nasopalatine Duct Cyst tissue in a
number of tissue specimens. Staining for KLK 9 showed great variability in the
Odontoma tissues. Enamel matrix stained profoundly with KLK 9 in Odontoma tissue.
This immunostaining shows a general trend for increased staining of KLK 9 in
odontogenic cysts (Dentigerous Cyst, Lateral Periodontal Cyst) or cystic neoplasms
(KOT) compared to the solid, most clinically aggressive odontogenic neoplasm
(Ameloblastoma) or odontogenic hamartoma (Odontoma). KLK 9 has been identified as
a favourable prognostic marker in breast and ovarian cancer, and may once again be a
favourable marker for odontogenic pathologies (18, 21, 23) as it is less abundant in the
more aggressive ameloblastoma. The role of KLK 9, and its exact mechanism of action
conferring favourable prognosis in the aforementioned malignancies is not yet identified,
and could be investigated with respect to the specific pathogenesis of odontogenic
cysts/tumours. Clinical treatment of the Dentigerous Cyst and Lateral Periodontal Cyst is
simple enucleation; low rates of recurrence are achieved with this treatment modality (57, 11). Treatment for the benign cystic neoplasm, the KOT is controversial, but en-bloc
resection with a margin of unaffected tissue is not indicated as a first line of therapy as it
is in management of the Ameloblastoma (5-7, 11). The Ameloblastoma is known to have
high rates of recurrence partly due to tumour cells extending beyond the radiographically
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visualized margin of the lesion. Malignancies can invade, fragment and metastasize, all
features correlated with worse prognosis. If KLK 9 is involved in the prevention of
budding or fragmentation of tumours, it could explain a possible role of KLK 9 based on
its pattern of identification in our study, and those identifying it as a favourable marker in
breast and ovarian malignancy.
KLK 9 was not identified in the Ameloblastoma when investigating mRNA
expression using RT-PCR. In order to investigate the expression and localization of KLK
9, RT-PCR would once again be useful to investigate the less clinically aggressive
odontogenic cysts/tumours, the Dentigerous Cyst, Lateral Periodontal Cyst and KOT for
the presence and abundance of KLK 9. If not present, KLK 9 protein may be recruited to
these lesions where it may function in a regulatory cascade. Correlation of the natural
history/clinical manifestation of many Ameloblastomas of variable clinical course (i.e.
Unicystic Ameloblastoma vs Solid Ameloblastoma vs Peripheral Ameloblastoma) with
the individual tumour’s specific KLK 9 expression could help to determine if KLK 9 is a
positive prognostic indicator in this specific lesion. If higher abundance of KLK 9
expression in Ameloblastoma tissue could be identified on initial incisional biopsy, and
research indicated that higher expression of KLK 9 confers favourable prognosis (less
likely to recur), it may be possible to tailor surgical therapy to the unique biology of a
patient’s tumour. At the present time, this is only a theoretical consideration; studies with
more power, specific clinical correlation and long term follow up would be required in
order to make this a potential reality.
KLK 11 staining was identified in all six tissue types investigated in this study.
KLK 11 staining was significantly greater in the Ameloblastoma than in the nonodontogenic control, the Nasopalatine Duct Cyst. In the KOT, well-formed keratin
stained intensely when desquamating, while in specimens with no visible desquamating
keratin, immunostaining was less intense. This qualitative finding that KLK 11 staining
was more intense in KOT lesions with visible desquamating keratin suggests that KLK
11 may have a role in the epithelial turnover, and/or that it may be sequestered in
desquamated keratin once these cells desmosomal attachment is lost. It may function in
conjunction with KLK 5 as part of this process. Desmosomal staining was visualized
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with staining of the Dentigerous Cyst. The Dentigerous Cysts also exhibited intense
nuclear staining of epithelial cells. The enamel matrix of Odontoma stained intensely for
KLK 11. KLK 11 is known to be present in non-malignant prostate tissue, is involved in
the desquamation of vaginal epithelium and is a favourable prognostic marker in ovarian
cancer. The nonspecific identification of KLK 11 in all six tissue types studied suggests
it may be involved in normal cell turnover, or ubiquitous processes within cells of
ectomesenochymal origin.
Kallikrein proteins have been utilized as biomarkers, most notably in the
monitoring and surveillance of prostate cancer. A more complete review of their roles as
biomarkers is provided in the introduction of this thesis. Kallikrein proteins have not yet
been identified as biomarkers in pathology of the head and neck. Due to the diverse array
of odontogenic pathologies that present in the maxillofacial region, as well as the
relatively similar clinical and radiographic findings (especially in the early stages of
growth) of lesions with variable clinical behaviour/natural history, tissue biopsy is
recommended prior to definitive surgical management of these lesions.
In addition to identifying biomarkers in serum, saliva is another non-invasive
source of systemic proteins for use in clinical decision making (59-61). Quantification of
KLK protein in saliva or serum could potentially act as an adjunct, or sole pre-operative
test prior to the definitive surgical management of various odontogenic pathologies. This
could allow a patient to undergo the appropriate operative intervention without having a
surgical incisional biopsy of the intraosseous lesion of interest. The ability to identify
easily accessible biomarkers for these lesions would be especially useful in populations
of individuals without access to surgical consultation. In Canada, this would include
individuals geographically isolated such as those in remote northern communities.
Worldwide, this would involve many groups of people in non-industrialized areas
without easy access to comprehensive medical care. If a relatively indolent process such
as the lateral periodontal cyst was identified based on biomarker analysis, it may not be in
the patient’s best interest to travel a significant distance in order to have formal biopsy, or
removal of the lesion, while if an aggressive lesion such as an ameloblastoma was
identified, it would be worth seeking surgical consultation.
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In addition to their role in identifying specific diseases/lesions, the presence or
absence of specific biomarkers may confer a positive or negative prognosis. It could be
possible that biomarkers (such as KLKs) may be identified in the Ameloblastoma or
KOT that predict their likelihood for recurrence. With this information, the surgical
intervention could be individualized for the specific pathology in each individual; the
generation of databases with proteomic profiles could be used to provide personalized
medicine to patient’s with these lesions.
While our methodology does not investigate the KLK proteins for their potential
role as biomarkers, it does provide the first step required to consider further investigation.
The pattern of expression of KLK genes and KLK protein identified in this data suggest
that low levels of KLK 9 are correlated with more aggressive odontogenic pathology (the
Ameloblastoma). The presence of KLK 5 in serum or saliva in the context of an
odontogenic lesion would possibly be indicative of a KOT due to its unique expression in
the parakeratin layer of the KOT and not in other odontogenic tumours/cysts. The
identification of KLK 3 protein/staining in benign odontogenic neoplasms in greater
amounts than in less clinically aggressive cysts could possibly provide another usage of
KLKs as biomarkers, as identification of KLK 3 may narrow a differential diagnosis to
one of these more aggressive lesions when compared to lesions with less expression of
KLK 3.
While there are a number of theoretical links based on the preliminary research
outlined in this thesis, a significant amount of further research would be required to
consider using KLKs as biomarkers for odontogenic cysts and tumours. Due to the
ubiquitous nature of KLK proteins in multiple organ systems, it may not materialize as a
clinically relevant investigation even with differential expression of KLK proteins within
the various odontogenic pathologies. It seems that the most likely utilization of
differential quantification of KLK proteins/analysis of the relative abundance of KLK
would be in determining the relative propensity for a specific patient’s tumour/cyst to
recur or grow. This could be based on KLK profile using serum or salivary fluid to
evaluate biomarkers, or through the use of immunostaining in histopathologic diagnosis.
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Immunohistochemistry is an appropriate method to investigate tissue for the
presence of protein, but is not without limitations. The analysis used is a validated
subjective assessment (25, 49, 50, 58) requiring the input from experienced independent
observers to quantify the magnitude of staining. In the process of analysis of the
immunostained slides, we attempted to use a computer based analysis of staining
intensity in order to provide more objective data on the staining intensity. Unfortunately,
due to the minimal volume of tissue to be analyzed (i.e. a single or double cell layer of
enamel epithelium around odontomas, or 2-5 cell thick Lateral Periodontal Cyst) or
varying, unpredictable location of cells of interest (Ameloblasts in various patterns of
Ameloblastomas), it was extremely time consuming and not easy to outline the tissue to
be analyzed while tissue remained on the slide. Additionally, special care must be taken
to be consistent in the specific tissue and cell types (i.e. pre-ameloblasts, clear cells,
enamel, dentin) included and excluded in the analysis to prevent error in the
interpretation from inconsistent comparison between tissue types. As a result of these
technical difficulties, we abandoned the idea of using a computer-based assessment of
immunostaining.
Another limitation of our study design was the limited abundance of odontogenic
epithelium in Odontoma specimens. This may have contributed to the larger standard
deviation found within the overall staining score for the Odontoma compared to other
tissue types where odontogenic or non-odontogenic epithelium is more abundant. To
maximize the volume of normal odontogenic epithelium (i.e. not associated with a
pathologic condition derived from the odontogenic epithelium) for study purposes,
developing dental follicles taken from aborted fetuses could be used as an odontogenic
control. Due to ethical concerns, we decided that it would be appropriate to use
Odontoma specimens, as these hamartomas mimic normal odontogenesis and are often
associated with adjacent odontogenic epithelium. In the pre-study selection of tissue, we
reviewed many Odontoma specimens from the Division of Oral Pathology archives, and
made sure to choose Odontoma specimens with some odontogenic epithelium to allow
histopathologic analysis of staining.
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Using immunohistochemistry to identify and attempt to measure KLK protein, we
cannot be certain whether the staining is due to KLK protein sequestered within the
tumour/tissue of interest, or if it is actually produced by the tissue/tumour being
investigated. While we can make statements about the identification of protein in tissue
types, postulate about the utility of KLK protein as a biomarker, or use variable patterns
of expression for aid in tissue diagnosis, we cannot make conclusions about the
production of these proteins by various tumours/cysts/tissues. As a result, the
implications of our findings are less powerful than if investigation about the production
of protein, or expression of mRNA was also performed. In order to obtain a more
complete understanding of the expression of KLK genes, mRNA and production of
protein, we can utilize other techniques to investigate for the presence of KLK mRNA.
Comparing information obtained through the reverse transcription-polymerase chain
reaction (to examine for the presence of KLK specific mRNA in tissue) with results from
immunostaining provides more insight into the role of KLK’s in these tumours/cysts of
interest. Using RT-PCR we are able to see whether or not the KLK genes are active, and
can identify specific KLK mRNA in the tissues of interest.

7.2

Expression of Ameloblastoma KLK mRNA Using RTPCR
RT-PCR evaluation of pooled Ameloblastoma tissue revealed the presence of

KLK mRNA for KLK 1, 4, 7, 8, 10 & 12. KLK mRNA was not identified for KLK 2, 3, 5,
6, 9, 11, 13, 14 or 15. KLK 3, 4, 9 and 11 proteins were identified in Ameloblastoma
tissue utilizing immunostaining as described previously in this thesis. Prior work from
our laboratory resulted in the identification of KLK 6, 7, 8, 10, 13 and 14 in
Ameloblastoma tissue utilizing immunohistochemistry and the identical analysis of
immunostaining performed in this study (58). Immunostaining was not performed for
KLK 1, 2, 12 and 15 due to unavailability of antibodies to complete the staining
procedure. Combining the findings of this study, with those previously identified from
our lab, we have identified that KLK 4, 7, 8, and 10 protein and KLK 4, 7, 8 and 10
mRNA are present in the Ameloblastoma. KLK mRNA was only identified (protein not
studied) for KLK 1 and 12. KLK protein but not KLK mRNA was identified for KLK 3,
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6, 9, 11, 13 and 14 when combining the findings of this thesis with prior work from our
laboratory (58). The co-identification of KLK protein and KLK mRNA strongly suggest
that the Ameloblastoma tissue produces KLK 4, 7, 8 and 10 proteins. We cannot
comment on the relationship between KLK 1 and 12 mRNA and KLK 1 and 12 proteins
since no immunostaining was performed for KLK 1 and 12. The identification of the
respective KLK protein with immunostaining for all other KLKs with mRNA identified
(KLK 4, 7, 8, and 10) in this study suggests that KLK 1 and 12 protein are likely also
found in the ameloblastoma tissue.
KLK 3, 6, 9, 11, 13 and 14 may be recruited to the Ameloblastoma, and
sequestered in the tumour tissue resulting in the identification of these proteins with
immunostaining, while their respective mRNA was not identified using the PCR
methodology in this study. Alternatively, the protein may have a long half life and
remain in the tissue despite low levels of mRNA expression locally at the time of
analysis. KLK 3, 6, 9, 11, 13 and 14 mRNA may be degraded rapidly following
production, or may be present in levels below the threshold that can be identified with
this method of PCR analysis. In order to evaluate for the presence of KLK mRNA where
KLK protein was identified but no mRNA identified, a nested PCR analysis could be
performed, where KLKs are amplified, allowing for greater detection capabilities.
Alternatively, the use of fresh tissue samples may provide the ability to identify mRNA
not identified in our study. The relative abundance of KLK 7 and 10 was higher than that
observed for KLK 1, 4, 8 and 12, while the overall staining scores for KLK 7 (6.1 +/- 0.9)
and KLK 10 (7.5 +/- 0.7) were within the range observed for KLK 4 (7.5 +/- 0.7) and
KLK 8 (6.9 +/- 0.3) (58), suggesting that the abundance of mRNA expression does not
correlate with magnitude of protein expression. Post-transcriptional modification of
mRNA, alterations in translation or post-translational modification or degradation of
KLK protein are all possible mechanisms that may account for the absence of a direct
relationship between KLK protein and mRNA expression.
Similar to the difficulty described in attempts at utilizing computer based analysis
to quantify staining in the small volume of odontogenic tissue of interest with
immunostaining, attempts to use a Laser capture microscope to isolate specific
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odontogenic epithelium for future use in RT-PCR proved not feasible due to the thin
cysts of interest and technical difficulty with the use of the cutting and capturing feature
of the microscope. After multiple attempts to use this technique, it was also abandoned
in favour of grouping tumours from multiple patient specimens in order to increase the
amount of tumour tissue. As a result, pooled Ameloblastoma tissue containing both
Ameloblastoma and adjacent tissue from the formalin fixed biopsy specimens were
pooled and utilized.
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Chapter 8

8

Conclusions
For the first time, human kallikrein protein 3, 4, 5, 9 and 11 have been identified

in odontogenic cysts and tumours. In addition, expression of KLK 1, 4, 7, 8, 10 and 12
mRNA was identified in the Ameloblastoma.
Specific protein expression patterns were identified utilizing Immunostaining.
KLK 3 was identified in all odontogenic cysts and tumours studied, as well as the nonodontogenic control, the developmental maxillofacial cyst, the Nasopalatine Duct Cyst.
KLK 3 protein expression was greater in benign neoplasms of odontogenic origin, the
Ameloblastoma and KOT compared to odontogenic control, the Odontoma. KLK 4
expression was found in similar magnitude across all odontogenic cysts and tumours
investigated, and was also identified in the Nasopalatine Duct Cyst. KLK 5 was only
identified in the parakeratin layer of the KOT. No other tissues investigated exhibited
KLK 5 expression. KLK 9 was identified in all odontogenic cysts and tumours studied,
as well as in the non-odontogenic control, the Nasopalatine Duct Cyst. The Dentigerous
Cyst, KOT and Lateral Periodontal Cyst exhibited greater expression of KLK 9 compared
to the Ameloblastoma, and the Dentigerous Cyst and KOT exhibited greater expression
of KLK 9 compared to the Odontoma. KLK 11 staining was identified in all odontogenic
tissue, and the non-odontogenic tissue in this study. KLK 11 staining was significantly
greater in the Ameloblastoma than in the non-odontogenic control, the Nasopalatine Duct
Cyst.
Co-expression of KLK 4, 7, 8 and 10 protein and mRNA was present for the
Ameloblastoma. Expression of KLK 1 and 12 mRNA was also present in Ameloblastoma
tissue.
The ultimate role of KLK protein in odontogenic pathology is not yet identified.
For odontogenic pathology, KLK 5 appears to be a specific marker for the KOT. KLK 3
may have a role in the development of more aggressive odontogenic lesions; KLK 9 may
be involved in the development of less clinically aggressive odontogenic cysts/tumours.
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The relatively ubiquitous expression of KLK protein and KLK mRNA in
odontogenic and non-odontogenic tissues is in accordance with past research identifying
KLKs in signaling cascades in a wide range of tissues. Their specific roles in each tissue
are under investigation, and further investigation of the expression of KLK mRNA and
role of KLK protein may provide clues to the regulation and differentiation of
odontogenic epithelium in the formation of cysts and tumours. Using this information, it
may be possible to develop minimally invasive or medical therapeutic modulators of
tumour growth to improve clinical outcomes. If patterns of KLK expression that
correlate with the propensity of tumours or cysts to recur could be identified, it may be
possible to use this information to perform individualized medicine for patients with
these pathologies. Further research is required on these topics.
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